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Abstract
Cancer remains a major health problem around the globe. Among various types
of treatments, plants have been shown to have great capacity in cancer treatment, one
of which, is Rhus coriaria. Commonly known as sumac, Rhus coriaria is a culinary
herb that is known to possess different therapeutic values including anti-oxidant and
anti-microbial activities.
In this PhD project, we tested the effect of Rhus coriaria extract (RCE) on the
migration, invasion and metastasis of MDA-MB-231 human breast cancer cells. We
showed that non-cytotoxic concentrations of RCE inhibited migration and invasion,
blocked adhesion to fibronectin and downregulated MMP-9. Additionally, we found
that RCE reduced VEGF production and downregulated the inflammatory cytokines
TNF-α and IL-6. The suggested mechanism for the effect of RCE appears to be through
inhibiting NFκB and STAT3 pathways. Moreover, we extended our study and
investigated the anti-cancer effect of RCE on HT-29 and Caco-2 human colorectal
cancer cells. We found that RCE inhibited the viability and colony growth of colon
cancer cells. RCE also induced Beclin-1-independent autophagy and caspase-7dependent apoptosis. The suggested mechanism through which RCE exerts its effect
is by inactivating AKT/mTOR pathway and downregulating Beclin-1, p53 and procaspase-3 through targeting them to proteasome-dependent degradation. Proteasome
inhibition restored these proteins to level comparable to control cells and reduced
RCE-induced cell death and blocked the activation of autophagy and apoptosis.
Proteasomal degradation of mTOR was concomitant with an overall increase in
proteins ubiquitination which target the proteins for degradation by the proteasome.
In conclusion, these preliminary results make Rhus coriaria a promising
therapeutic candidate against both breast and colorectal cancer.
Keywords: Rhus coriaria, breast cancer, colorectal cancer, apoptosis, autophagy,
proteasome.
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)Title and Abstract (in Arabic

دراﺳﺔ اﻵﻟﯾﺔ اﻟﺟزﯾﺋﯾﺔ اﻟﺗﻲ ﯾﻘوم ﻣن ﺧﻼﻟﮭﺎ ﻧﺑﺎت اﻟﺳﻣﺎق ﺑﻧﺷﺎطﮫ اﻟﻣﺿﺎد ﻟﻣرض
اﻟﺳرطﺎن
اﻟﻤﻠﺨﺺ

ﯾ ﻌ ﺪ ﻣ ﺮ ض اﻟﺴ ﺮ ط ﺎن ﺧ ﻄ ﺮ ا ً ﺻ ﺤ ﯿ ﺎ ً ﻓ ﻲ ﺟ ﻤ ﯿ ﻊ أﻧﺤ ﺎء اﻟﻌ ﺎﻟﻢ  ،و ﻣ ﺎز اﻟ ﺖ ﻋ ﻤ ﻠﯿﺔ اﻟﺒﺤ ﺚ ﻋ ﻦ
ﻋ ﻼ ﺟ ﺎ ت ﻟﮭ ﺬ ا اﻟﻤ ﺮ ض ﻣ ﺴ ﺘﻤ ﺮ ة  ،و ﻣ ﻦ ﺿ ﻤ ﻦ ھ ﺬ ه اﻟﻌ ﻼ ﺟ ﺎ ت اﺳ ﺘﺨ ﺪ ام اﻟﻨﺒ ﺎﺗ ﺎ ت و ﻣ ﺸ ﺘ ﺎﻗ ﺎﺗﮭ ﺎ ﻟﺼ ﻨ ﺎﻋ ﺔ
أ د و ﯾ ﺔ ﻣ ﻀ ﺎ د ة ﻟ ﻠﺴ ﺮ ط ﺎ ن  .أ ﺣ ﺪ ھ ﺬ ه ا ﻟ ﻨ ﺒ ﺎ ﺗ ﺎ ت و ا ﻟ ﺬ ي ﻻ ﻗ ﻰ ا ھ ﺘ ﻤ ﺎ ﻣ ﺎ ً ھ ﻮ ﻧ ﺒ ﺎ ت ا ﻟ ﺴ ﻤ ﺎ ق أ و ﻛ ﻤ ﺎ ﯾ ﻌ ﺮ ف
ﺑﺎﺳﻤﮫ اﻟﻌﻠﻤﻲ ) (Rhus coriariaﺣﯿﺚ أﺷﺎرت اﻟﺪراﺳﺎت اﻟﺴﺎﺑﻘﺔ ﻋﻠﻰ ﻓﺎﻋﻠﯿﺘﮫ ﻛﻌﻼج ﻣﻀﺎد
ﻟﻸ ﻛ ﺴ ﺪ ة و ﻣ ﻀ ﺎ د ﺣ ﯿ ﻮ ي .
و ﻣ ﻦ ھ ﺬ ا ا ﻟ ﻤ ﻨ ﻄ ﻠ ﻖ ﻗ ﻤ ﻨ ﺎ ﻓ ﻲ ھ ﺬ ه ا ﻷ ط ﺮ و ﺣ ﺔ ﺑ ﺪ ر اﺳ ﺔ أ ﺛ ﺮ ﻣ ﺴ ﺘ ﺨ ﻠ ﺺ ﻧ ﺒ ﺎ ت ا ﻟ ﺴ ﻤ ﺎق ﻋ ﻠ ﻰ ﻧ ﻤ ﻮ
واﻧﺘﺸﺎر ﺧﻼﯾﺎ اﻟﺜﺪي اﻟﺴﺮطﺎﻧﯿﺔ  .MDA-MB-231وأﺷﺎرت ﻧﺘﺎﺋﺞ ھﺬه اﻟﺪراﺳﺔ إﻟﻰ أن اﺳﺘﺨﺪام
ﺗ ﺮ ﻛ ﯿ ﺰ ا ت ﻣ ﻨ ﺨ ﻔ ﻀ ﺔ ﻻ ﺗ ﻘ ﺘ ﻞ ا ﻟ ﺨ ﻼ ﯾ ﺎ ﻣ ﻦ ﻣ ﺴ ﺘ ﺨ ﻠ ﺺ ا ﻟ ﺴ ﻤ ﺎ ق ﺣ ﺎ ﻟ ﺖ د و ن ﻏ ﺰ و و ا ﻧ ﺘ ﺸ ﺎ ر ا ﻟﺨ ﻼ ﯾ ﺎ
اﻟﺴﺮطﺎﻧﯿﺔ وﻣﻨﻌﺖ ارﺗﺒﺎط ھﺬه اﻟﺨﻼﯾﺎ ﺑﺒﺮوﺗﯿﻦ ال  fibronectinﻛﻤﺎ أﻧﮭﺎ أدت إﻟﻰ ﺧﻔﺾ
ﻣﺴﺘﻮﯾﺎت ﺑﺮوﺗﯿﻦ ال  .MMP-9ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ ﻓﻘﺪ وﺟﺪﻧﺎ أن اﻟﺴﻤﺎق ﯾﻘﻠﻞ ﻣﻦ إﻓﺮاز ﻛﻞ ﻣﻦ
 VEGFو TNF-αو .IL-6وﻋﻠﻰ ﻣﺎ ﯾﺒﺪو ﻓﺈن اﻵﻟﯿﺔ اﻟﻤﻘﺘﺮﺣﺔ ﻟﻌﻤﻞ ﻣﺴﺘﺨﻠﺺ اﻟﺴﻤﺎق ﺗﺘﻤﺜﻞ ﻓﻲ
ﺗﺜﺒﯿﻂ ﻣﺴﺎرات  NFκBو .STAT3ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ ﻗﻤﻨﺎ ﺑﺪراﺳﺔ أﺛﺮ ﻣﺴﺘﺨﻠﺺ اﻟﺴﻤﺎق ﻋﻠﻰ
ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﻘﻮﻟﻮن  HT-29و ،Caco-2ووﺟﺪﻧﺎ أن ﻣﺴﺘﺨﻠﺺ اﻟﺴﻤﺎق ﯾﻤﻨﻊ ﻧﻤﻮ ﺧﻼﯾﺎ ﺳﺮطﺎن
اﻟﻘﻮ ﻟﻮ ن اﻟﻤ ﻔﺮ د ة ﻣ ﻨﮭ ﺎ و اﻟﺘ ﻲ ﻛ ﻮ ﻧ ﺖ ﻣ ﺴ ﺘﻌ ﻤ ﺮ ات  ،ﻛ ﻤ ﺎ و ﺟ ﺪ ﻧ ﺎ أ ن اﻟﻤ ﺴ ﺘﺨ ﻠﺺ أ د ى إﻟ ﻰ ﻋ ﻤ ﻠﯿﺔ اﻻ ﻟﺘﮭ ﺎ م
اﻟﺬاﺗﻲ اﻟﺘﻲ ﻻ ﺗﻌﺘﻤﺪ ﻋﻠﻰ ﺑﺮوﺗﯿﻦ  Beclin-1وأدى إﻟﻰ ﻣﻮت اﻟﺨﻼﯾﺎ اﻟﻤﺒﺮﻣﺞ اﻟﻤﻌﺘﻤﺪ ﻋﻠﻰ
 .caspase-7واﺳﺘﻨﺎدا ً ﻋﻠﻰ ھﺬه اﻟﻨﺘﺎﺋﺞ ﻓﺈن اﻵﻟﯿﺔ اﻟﻤﻘﺘﺮﺣﺔ اﻟﺘﻲ ﻣﻦ ﺧﻼﻟﮭﺎ ﯾﻤﺎرس اﻟﻤﺴﺘﺨﻠﺺ
ﺗﺄﺛﯿﺮه ھﻮ ﺗﻌﻄﯿﻞ ﻣﺴﺎر  AKT / mTORوﺗﻘﻠﯿﻞ ﻣﺴﺘﻮﯾﺎت اﻟﺒﺮوﺗﯿﻨﺎت اﻟﺘﺎﻟﯿﺔ  Beclin-1وp53
و pro-caspase-3ﻋﻦ طﺮﯾﻖ ﺗﺤﻠﯿﻞ ھﺬه اﻟﺒﺮوﺗﯿﻨﺎت ﻓﻲ اﻟﺒﺮوﺗﯿﻮزوم .وﻟﻠﺘﺤﻘﻖ ﻣﻦ ذﻟﻚ ﻗﻤﻨﺎ
ﺑ ﺘ ﺜ ﺒ ﯿ ﻂ ا ﻟ ﺒ ﺮ و ﺗ ﯿ ﻮ ز و م و ﻋ ﺎ ﻟ ﺠ ﻨ ﺎ ﺧ ﻼ ﯾ ﺎ ﺳ ﺮ ط ﺎ ن ا ﻟﻘ ﻮ ﻟ ﻮ ن ﺑ ﻤ ﺴ ﺘ ﺨ ﻠ ﺺ ا ﻟ ﺴ ﻤ ﺎ ق  ،و و ﺟ ﺪ ﻧ ﺎ أ ن ﻣ ﺴ ﺘ ﻮ ﯾ ﺎ ت
اﻟﺒﺮ و ﺗﯿﻨ ﺎ ت ﻋ ﺎ د ت إﻟﻰ ﻣ ﺴ ﺘﻮ ﯾ ﺎ ت ﺗﺸ ﺒﮫ اﻟﻤ ﺠ ﻤ ﻮ ﻋ ﺔ اﻟﻀ ﺎﺑﻄ ﺔ ﻣ ﻦ ا ﻟﺨ ﻼ ﯾ ﺎ و اﻟﺘ ﻲ ﺑ ﮭ ﺎ ﻧﻘ ﺎر ن اﻟﺨ ﻼ ﯾ ﺎ
اﻟﻤ ﻌ ﺎﻟﺠ ﺔ  .ﻛ ﻤ ﺎ أن اﺳ ﺘﺨ ﺪ ام ﻣ ﺜﺒﻂ اﻟﺒﺮ و ﺗﯿﻮ ز و م أد ى إﻟﻰ اﻟﺘﻘﻠﯿ ﻞ ﻣ ﻦ ﻣ ﻮ ت اﻟﺨ ﻼ ﯾ ﺎ ﻛ ﻤ ﺎ ﻣ ﻨﻊ ﺣ ﺪ و ث
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ﻋ ﻤ ﻠ ﯿ ﺘ ﻲ اﻻ ﻟ ﺘ ﮭ ﺎم اﻟ ﺬ ا ﺗ ﻲ و ﻣ ﻮ ت اﻟﺨ ﻼ ﯾ ﺎ اﻟﻤ ﺒﺮ ﻣ ﺞ  .و و ﺟ ﺪ ﻧ ﺎ أ ﯾ ﻀ ﺎ ً أن ا ﻧﺨ ﻔ ﺎ ض ﻣ ﺴ ﺘ ﻮ ى ﺑﺮ و ﺗ ﯿ ﻦ
 ،mTORﻛﺎن ﻣﺼﺎﺣﺒًﺎ ﻟﻠﺰﯾﺎدة اﻟﻜﻠﯿﺔ ﻓﻲ ﻣﺴﺘﻮى ﺑﺮوﺗﯿﻨﺎت  ubiquitinواﻟﺘﻲ ﺗﻌﻤﻞ ﻋﻠﻰ ﺗﻮﺟﯿﮫ
اﻟﺒﺮ و ﺗﯿﻨ ﺎ ت ﻟﻠﺘﺤ ﻠﯿ ﻞ ﺑﻮ اﺳ ﻄ ﺔ اﻟﺒﺮ و ﺗﯿﻮ ز و م .
ﻓ ﻲ اﻟﺨ ﺘ ﺎم  ،ﻓ ﺈن ھ ﺬ ه اﻟﻨ ﺘ ﺎ ﺋﺞ اﻷ و ﻟﯿﺔ ﻣ ﻦ اﻟﺒﺤ ﺚ ﺗﻠﻘ ﻲ اﻟﻀ ﻮ ء ﻋ ﻠﻰ ﻧﺒ ﺎ ت ا ﻟ ﺴ ﻤ ﺎ ق و ﺗ ﺠ ﻌ ﻠ ﮫ
ﻣﺮﺷًﺤﺎ واﻋﺪا ً ﻟﻠﻌﻼج واﻟﻮﻗﺎﯾﺔ ﺿﺪ ﺳﺮطﺎن اﻟﺜﺪي وﺳﺮطﺎن اﻟﻘﻮﻟﻮن.
ﻣ ﻔ ﺎھ ﯿ ﻢ ا ﻟ ﺒ ﺤ ﺚ ا ﻟﺮ ﺋ ﯿ ﺴ ﯿ ﺔ  :ﻧ ﺒ ﺎ ت ا ﻟ ﺴ ﻤ ﺎق  ،ﺳ ﺮ ط ﺎ ن ا ﻟ ﺜ ﺪ ي  ،ﺳ ﺮ ط ﺎ ن ا ﻟﻘ ﻮ ﻟ ﻮ ن  ،ا ﻟ ﻤ ﻮ ت ا ﻟ ﻤ ﺒ ﺮ ﻣ ﺞ ﻟ ﻠ ﺨ ﻼ ﯾ ﺎ ،
اﻻ ﻟﺘﮭ ﺎم اﻟﺬ اﺗ ﻲ ﻟﻠﺨ ﻼ ﯾ ﺎ ،اﻟﺒﺮ و ﺗﯿﺰ و م .
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Chapter 1: Introduction
1.1 Cancer
1.1.1 A brief history of cancer
Cancer has been known to humanity since ancient times. Cancer develops
when cells in a specific part of the body turn to grow out of control. One of the primary
proofs of the existence of cancer was revealed in fossilized bone tumors in human
mummies in ancient Egypt. As it was documented in ancient manuscripts, bony skull
damage was seen in the head and neck. The disease was firstly entitled cancer by the
Greek physician Hippocrates, father of medicine, who used Greek words “carcinoma”
and “Karakinos” to describe a tumor; these terms were used to describe crab movement
[1-3].
1.1.2 Epidemiology
Cancer continues to be a health burden globally; it is the second leading cause
of death accounting to an estimated 9.6 million deaths in 2018 [4]. Cancer is a
multifactorial disease that is characterized by uncontrolled cellular division, invasion
and spreading of those cells from their primary site to other sites in the body to establish
new colonies of cancer cells [5].

1.1.3 Hallmarks of cancer
Cancer cells are distinguished from normal cells by gaining specific hallmarks.
These hallmarks include acquiring autonomous growth by secreting their own signals
and growth factors to maintain their proliferation state. Moreover, cancer cells can
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escape inhibitory signals that might otherwise stop their growth. In addition, evading
apoptosis by escaping the regulation of the tumor suppressor genes and enabling
unlimited replicative potential through upregulation of oncogenes. Additionally,
inducing angiogenesis which is the process of formating new blood vessels to get
nutrient supply that will promote their tumorigenesis. Cancer also invade local tissues
and migrates to distant organs in a process called metastasis [6]. Emerging hallmarks
of cancer were also described; these hallmarks include genome instability and
mutation, promoting inflammation, avoiding immune destruction and reprogramming
energy metabolism [7].
1.1.4 Classification of cancer
Cancers are very diverse; more than one hundred different types of cancers
have been identified. According to the type of tissue in which they originate, cancers
were classified into five main groups, which are carcinoma, sarcoma, myeloma,
leukemia and lymphoma. Carcinoma starts in epithelial tissues, while sarcoma is found
in mesoderm derived cells such as bone and muscle. Myeloma originates in the plasma
cells of bone marrow. Moreover, leukemia is a cancer that is found in the bone marrow
and lymphoma develops in the glands or nodes of the lymphatic system [8, 9].
1.1.5 Causes of cancer
While the real cause of cancer is still unknown, many factors have been
associated with cancer. These factors include genetic mutations in tumor suppressor
genes and oncogenes. Tumor suppressor genes are present in the cells to promote cell
death and suppress cell division such as tumor protein 53 (P53) and retinoblastoma
protein (RB), while oncogenes are important in promoting cell division and
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proliferation such as c-myc and Ras. Life style can also be a risk factor such as
smoking, UV radiation and obesity. Chemical agents that can cause cancer are called
carcinogens and these includes cadmium, arsenic, nitrosamines and aflatoxins. Viruses
can also lead to cancer development such as human papillomavirus which can cause
cervical cancer, Helicobacter pylori virus which can cause gastric cancer and hepatitis
virus B which can cause hepatocellular carcinoma [8].
1.2 Breast cancer
Breast cancer remains one of the most common cancers as well as one of the
leading causes of worldwide cancer-related mortality. It is the second most common
cancer worldwide accounting for 2.09 million cases in 2018 and it is the fifth most
common cause of cancer-related deaths accounting for 627,000 deaths in 2018 [10].
There are a number of factors correlated with an increased risk of breast cancer such
as age, family history, exposure to radiation [5] and lifestyle [6] .
Breast cancers are heterogeneous and diverse group of diseases that come with
several clinical and histological implications. The clinical progression of breast cancer
is difficult to predict, and its current treatment is, therefore, not as effective as it should
be [11, 12]. Breast tissues are made up mainly of lobules, ducts and stroma. From these
different types of breast cells breast cancer originates [13, 14]. Breast cancers can be
classified according to their histopathology and protein profile and gene expression
[15].
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1.2.1 Histopathological classification of breast cancer
Breast cancers can be classified according to their histopathological
characteristics into lobular neoplasia, ductal carcinoma in situ and invasive ductal
carcinoma. Lobular neoplasia is composed of noninvasive lesions, such as atypical
lobular hyperplasia, lobular carcinoma in situ and invasive lobular carcinoma. Ductal
carcinoma in situ is characterized by the proliferation of malignant cells within the
ducts without invasion of the surrounding stromal tissue. Finally, the invasive ductal
carcinoma which is the most common invasive carcinoma of the breast [16-18].

1.2.2 Molecular classification of breast cancer
The molecular classification of breast cancer is based on examining the
alterations of gene expression that drive cancer. This is important as it has prognostic
significances beyond the traditional prognostic indexes and can aid in the
determination of the most suitable treatment for the individual. Using hierarchical
cluster analysis; breast cancers can be classified into five molecular subtypes: luminal
A and luminal B, basal-like, human epidermal growth factor receptor 2 (HER2)
overexpression, and normal breast-like [11, 19, 20].
1.2.3 Triple negative breast cancers
Triple negative breast cancer (TNBC) represents a heterogeneous subtype of
breast cancers that belongs mainly to the basal-like breast cancers and is associated
with an aggressive clinical conditions, where targeted therapies are currently limited
[21]. TNBC is a diagnosis of exclusion since those cells are known to lack the
expression of estrogen receptor (ER), progesterone receptor (PR) and human
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epidermal growth factor receptor (HER2) [22]. TNBC is considered to be highly
aggressive and have high proliferative index compared to other breast cancers [23].
Moreover, TNBC is characterized by distinctive patterns of metastasis which usually
include brain, lung and bone metastasis [24]. Additionally, they have poor prognosis
and relapse very quickly compared to other breast cancers [25]. Some of the TNBCs
are known to have BRCA1 mutations. Mutations in BRCA1, a gene that is essential
for DNA repair mechanism, accumulates DNA errors and causes genetic instability
which could lead to tumor growth [26].
1.3 Colorectal cancer
Colorectal cancer is the third most common cancer globally where 1.80 million
cases were recorded in 2018 [10]. It is the second leading cause of cancer related deaths
where 862,000 deaths were documented in 2018 [10]. Colorectal cancer affects both
sexes equally with poor survival rate once it metastasizes [27].
Colorectal cancer is a complex disease; it starts growing in the lining of the
colon and the rectum in a form of a polyp, which is a non-cancerous mass bulging in
the lumen. It is worth mentioning that not all polyps will develop into cancer [28].
During the development of colorectal adenocarcinoma, gastrointestinal epithelial cells
acquire consecutive genetic and epigenetic mutations in oncogenes and tumor
suppressor genes; these mutations in some cases might give the cells proliferative and
self-renewal abilities. Therefore, the transitioning epithelium cells become hyperproliferative which develops into a benign adenoma that might evolve into malignant
carcinoma that can spread and metastasize forming new tumor colonies in neighboring
organs [29].
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1.3.1 Risk factors
Genetic and environmental factors are crucial in the etiology of colorectal
cancer. A subgroup of colorectal cancer patients is affected by a hereditary colorectal
cancer syndrome. Lynch syndrome is the most common syndrome which is caused by
a mutation in one of the genes that are crucial in DNA mismatch-repair such as: MLH1,
MSH2, MSH6, PMS2 or EPCAM. Errors in mismatch repair mechanism during
replication gives rise to the accumulation of DNA mutations [27].
Colorectal cancer has seen an increase in incidents that now it became one of
the predominant cancers. A range of environmental lifestyle factors influence the risk
of developing colorectal cancer such as aging, poor diet and lifestyle, smoking, low
rate of physical activities and obesity [30].
1.3.2 Mechanisms and pathophysiology of colorectal cancer
Colorectal cancer develops when the previous mentioned risk factors promote
the acquisition of cancer hallmarks in colon epithelial cells. One possible way is
through the sequential and progressive accumulation of genetic mutations and
epigenetic alterations that aid in the activation of oncogenes and inactivation of tumor
suppressor genes [7, 31]. However, the majority of colorectal cancer follows what is
known as the classic model of formation, in which they arise from polyps that if left
unchecked might develop into an early adenoma which is less than 1 cm in size, with
tubular histology. Then the adenoma might obtain enough hallmarks to progress to an
advanced adenoma which is roughly the same size as the early adenoma, but, with
villous histology, before they are finally and fully becoming colorectal cancer. The
process from polyp formation to the development of colorectal cancer might take
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between 10 to 15 years [32]. Other types of colorectal cancer have been shown to
evolve from a subset of polyps called sessile serrated polyps [33] and are classified
into three categories: hyperplastic polyps, sessile serrated adenomas and traditional
serrated adenomas [34]. Sessile serrated polyps have the ability to transform into
colorectal cancer through the following sequence: hyperplastic polyp to sessile
serrated polyp to adenocarcinoma [35].
1.3.3 Molecular classification of colorectal cancer
Colorectal cancer can be classified into four different subgroups according to
their molecular features; these groups are hypermutable microsatellite stable,
hypermutable microsatellite unstable, microsatellite stable or chromosome unstable,
and CpG island methylator phenotype cancers. Mutations between the molecular
subclasses can differ dramatically which suggest that each subclass has its own set of
cooperating drivers [36]. Mutations as the ones that present in APC and SMAD4, are
common among all the molecular subgroups, while there are other mutations that are
restricted to one subgroup [37]. Not only genetic mutations occur in colorectal cancer,
but also epigenetic mutations which occur in polyps and colorectal cancer and seem
to cooperate in driving the polyp to develop into a cancer prototype. An example of an
epigenetic modification is the DNA methylation of CpG islands that can result in
transcriptional silencing. Aberrant gene methylation seems to increase most
significantly during the progression of early adenoma to advanced carcinoma [38].

8
1.4 Molecular targets in cancer treatment
1.4.1 Apoptosis
Apoptosis is a tightly orchestrated multi-step pathway where cells commit to
self-suicide. This mechanism of programmed cell death is extremely crucial during
development; however, it is also important in adult multicellular organisms’
homeostasis. Key characteristics of apoptosis are cellular shrinkage, condensation of
the nucleus and DNA fragmentation [39, 40]. Cells that undergo apoptosis initially
become rounded and retracted from neighboring cells which is accompanied by plasma
membrane blebbing [41, 42]. A dominant signal of apoptosis is the translocation of
phosphatidylserine from the inner to the outer side of the plasma membrane. This ‘eatme’ signal functions as a recognition signal for phagocytic cells to engulf apoptotic
cells [43]. Apoptosis occur in a controlled manner to minimize damage and disruption
to neighboring cells [39]. Apoptosis is orchestrated primarily by members of cysteine
proteases family known as caspases [44]. Apoptosis can be initiated through one of
two pathways; the extrinsic and the intrinsic pathways.
1.4.1.1 Apoptotic signaling pathways
1.4.1.1.1 Extrinsic pathway
The extrinsic pathway requires external stimulation; this will cause the
extracellular death ligands such as tumor necrosis factor-α (TNF-α) or FasL to bind to
transmembrane death receptors. Binding of death receptors with their corresponding
ligands provokes the recruitment of adaptor proteins, such as the Fas-associated death
domain protein (FADD), which in turn recruits caspase-8 and promotes its activation.
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Active caspase-8 proteolytically activates caspase-3 and -7, which cause further
caspase activation events that results in substrate proteolysis and cell death [42].
1.4.1.1.2 Intrinsic pathway
The intrinsic pathway is engaged by a wide array of stimuli that are sensed
intracellularly, including cytokine deprivation, DNA damage and endoplasmic
reticulum stress. These stimuli activate BH3-only family members, which inhibit the
pro-survival BCL-2-like proteins, thereby enabling the activation of the pro-apoptotic
effectors BAX and BAK, which then disrupt the mitochondrial outer membrane and
cause the release of cytochrome c. Cytochrome c promotes caspase-9 activation on the
scaffold protein apoptotic protease activating factor 1 (APAF1) which propagates a
proteolytic cascade of further caspase activation events [45].
1.4.1.2 Apoptosis in cancer
Apoptosis is widely considered as a positive process that both prevents and
treats cancer. Undoubtedly, having a beneficial role, apoptosis can also cause
unwanted effects that may even promote cancer. For instance, apoptotic cells release
different ‘eat-me’ and ‘find-me’ molecules to signal their removal by phagocytes.
These signals can have various tumorigenic effects, including turning tumorassociated macrophages towards a pro-oncogenic state. Additionally, death receptors
can function as promoting growth, invasion and survival of cells. Beyond defining the
dark side of apoptosis, some of these oncogenic effects also offer promising potential
to fight cancer through understanding how cancer cells tolerate failed apoptosis and
survive, which could provide new strategies to sabotage this process to kill cancer cells
[46].
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1.4.2 Autophagy
Lysosomes were first discovered and named by Christian de Duve and his
group in 1955 [47] and for that he earned a Nobel Prize in physiology or medicine in
1974 [48]. De Duve also called the delivery of intracellular material to the lysosome
“autophagy” as early as 1963, and he studied the regulation of autophagy by nutrient
availability [49]. Nevertheless, the mechanism of lysosomal delivery remained
unknown and research on autophagy did not receive much attention for more than 30
years. After that Yoshinori Ohsumi’s group conducted a genetic screening to dissect
autophagy process in yeast, and they identified 15 autophagy- related proteins (ATGs)
essential for autophagy process [50]. In 2016, Ohsumi was awarded a Nobel Prize in
physiology or medicine for his discovery of mechanisms of autophagy [51].
Autophagy is a highly regulated cellular process that can either result in the
degradation of proteins or it can specifically target distinct organelles i.e. mitochondria
in mitophagy and the endoplasmic reticulum in reticulophagy [52]. Autophagy starts
with the engulfment of damaged or unnecessary cellular content into a doublemembrane vesicle named autophagosome. Autophagosome is transported and fused
with the lysosome to form single-membrane autolysosome, in which the content would
be degraded and recycled [53]. Fundamentally, autophagy is a cellular survival
mechanism, where it mediates the turnover of protein aggregates that otherwise might
lead to cellular dysfunction. Nevertheless, if the cell acquired too many faults that
exceed its ability to salvage, then the cell could die due to autophagy destroying large
proportions of the cytoplasm that would result in an irreversible cellular atrophy;
consequently, collapse of crucial cellular functions and cell death [54, 55]. Autophagy
occurs in several steps that are depicted in Figure 1.

Figure 1: Overview of autophagy process [56]
11

12
1.4.2.1 Autophagic pathway
1.4.2.1.1 Initiation
Signals that activate autophagy originate from different conditions of stress,
such as starvation, oxidative stress, hypoxia and protein aggregation [56]. The
initiation of autophagic process requires the ULK complex [57]. Under nourished
conditions, the ULK complex is bound to the mammalian target of rapamycin complex
1 (mTORC1) and is, thus, inactive. However, upon amino acid starvation, the
mTORC1 becomes inactive and dissociates from the ULK complex, which results in
increased ULK1 and ULK2 kinase activity. The carboxy-terminal domain of ULK1
and ULK2 binds to the cellular membranes which is thought to mediate the recruitment
of the complex to the site of autophagosome initiation [58].
1.4.2.1.2 Nucleation
Once activated and targeted to the site of autophagosome initiation,
phagophore nucleation starts by the activation of Beclin-1 complex through its
phosphorylation. Beclin-1 complex consist of class III PI3K, vacuolar protein sorting
34 (VPS34), Beclin-1, ATG14, activating molecule in Beclin-1-regulated autophagy
protein 1 (AMBRA1) and general vesicular transport factor (p115) [59, 60]. ULK1
was shown to phosphorylate VPS34 which enhances the activity of the PI3K complex.
This will lead to the activation of local phosphatidylinositol-3-phosphate (PI3P)
production at a characteristic endoplasmic reticulum structure called the omegasome.
These previous events drive the nucleation of the phagophore membrane and the
recruitment of additional ATG proteins and autophagy-specific PI3P effectors, such as
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phosphoinositide-interacting proteins (WIPI ) [56].
1.4.2.1.3 Expansion
Following nucleation, WIPI2 binds to ATG16L1 directly; thus, recruiting the
ATG12~ATG5–ATG16L1 complex that enhances the ATG3-mediated conjugation of
ATG8 family proteins. These proteins include microtubule- associated protein light
chain 3 (LC3) proteins and γ- aminobutyric acid receptor- associated proteins
(GABARAPs) to membrane- resident phosphatidylethanolamine (PE). This enables
them to associate with the autophagosomal membrane in lipidized forms, therefore,
the cytosolic LC3-I will be converted into the lipidized LC3-II which is a characteristic
signature of autophagic membranes. The association of these cytosolic proteins and
protein complexes with the membrane occurs while the isolation membrane is
expanding [61]. Several cellular membranes, including the plasma membrane,
mitochondria, recycling endosomes and the golgi complex, contribute to the
elongation of the autophagosomal membrane by donating membrane material [56].
1.4.2.1.4 Cargo sequestering
During phagophore expansion, LC3-II binds to the adaptor protein
p62/sequestosome1 (P62/SQSTM1), which is involved in trafficking proteins to the
proteasome and serves to facilitate the autophagic degradation of ubiquitinated protein
aggregates [62]. The p62/SQSTM1 is normally degraded during autophagy and
accumulates when autophagy is impaired, as has been shown in autophagy-deficient
mice [63]. Aside from their contribution to phagophore expansion, ATG8 also
facilitate cargo recruitment in selective autophagy and LC3-II is critically involved in
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the sequestration of specifically labelled cargo into autophagosomes via LC3-II
interacting region that contains cargo receptors which themselves recognize the cargo
through ‘eat- me’ signals such as ubiquitin (Ub) or galectins [56].
1.4.2.1.5 Sealing
Before the closure of the phagophore, the ATG proteins that are bound to the
membrane dissociate, but LC3-II and its family members remain attached to the
membrane. LC3-II remains bound after the closure of the phagophore to the inner
membrane of the autophagosome [64]. LC3-II family members are thought to help in
the expansion and closure of the phagophore and their retention inside the closed
autophagosome provides an important and widely used marker for identifying
autophagosomes in cells [65].
1.4.2.1.6 Maturation and fusion
Autophagosomes undergo maturation by fusion with lysosomes to form
autolysosomes. After expansion and sealing of the phagophore, the machinery
responsible for lysosomal delivery which consists of microtubule- based kinesin
motors is recruited. Moreover, the machineries that mediate fusion with the lysosome
are recruited as well and those are: SNAREs (syntaxin 17 (STX17) and synaptosomalassociated protein 29 (SNAP29)) on the autophagosome, vesicle associated membrane
protein 8 (VAMP8) on the lysosome, and the homotypic fusion and protein sorting
(HOPS) complex which mediates membrane tethering to support SNARE- mediated
fusion. ATG8 drives maturation by linking the autophagosome to kinesins through
autophagy- specific kinesin adaptors [66, 67]. Post- translational modifications of
ATG8 further regulate autophagosome maturation, as the phosphorylation of LC3 on
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residue Thr50 by the Ste20 Hippo kinase orthologues serine/threonine protein kinase
3 (STK3) and STK4 was recently found to be essential for autophagosome–lysosome
fusion and for clearance of intracellular bacteria by autophagy. However, these
processes are still under investigation and need further characterization [68].
In the autolysosomes, the inner membrane and the luminal content of the
autophagic cargo are degraded by acidic hydrolases and recycled nutrients are released
back to the cytoplasm to be used again by the cell [69].
1.4.2.2 Autophagy role in cancer
The role of autophagy in cancer is complex and may differ depending on the
tumor type and conditions. It is suggested that upregulation of autophagy can either be
a cell protective mechanism or an alternative cell death mechanism. As a
cytoprotective function; it is believed that autophagy has tumor- suppressive potential
before the onset of tumorigenesis, and loss of autophagy has been associated with
increased risk of cancer as autophagy protects cells from the genotoxic stress that can
lead to oncogenic transformation [70, 71]. However, some investigators have
hypothesized that once the tumor has formed, it will use autophagy process as a
survival mechanism to overcome the stresses imposed during cancer progression, as
well as those caused by radiation or chemotherapy [72]. Other researchers have
suggested that autophagy might suppress tumorigenesis by inducing cell death [73].
Therefore, depending on the type of tumor and its developmental stage,
activation or inactivation of autophagy can contribute differently to tumorigenesis. A
better understanding of the autophagy in tumor models is crucial in identifying new
and effective therapeutic strategies for cancer treatment.
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1.4.3 Ubiquitin proteasome system
The ubiquitin proteasome system (UPS) is a highly regulated and extremely
selective cellular mechanism of protein degradation. The degradation of most nuclear
and cytosolic proteins is the responsibility of the UPS, including misfolded proteins,
short-lived as well as long-lived proteins. Protein degradation by the UPS is highly
precise, involving the concerted functions of series of enzymes. Proteins are marked
for degradation by the attachment of a Ub chain to them [74, 75].
The UPS degrades a massive variety of proteins that contain specific
degradation signals, or degrons. A degron is defined as a minimal element within a
protein that is sufficient for recognition and degradation by the proteasome. To allow
substrate unfolding and translocation into the proteasome, degrons require specific E3binding determinants, an appropriate Ub modification site and a proteasomal
degradation initiation site. The most common acceptor site for polyubiquitin chain
addition is on the lysine. Degron activity is regulated in many ways. One way is
through post-translational modifications which activate many degrons such as protein
phosphorylation, hydroxylation and proteolytic cleavage [76].
Ubiquitination is recognized by receptors on the proteasome. Proteins are
unfolded and passed into the catalytic chamber for digestion. Proteolysis is
irreversible, making it a powerful mechanism for imposing directionality on a system,
as shown by its use in controlling the cell cycle [77].
1.4.3.1 The mechanism of UPS
The initiation of proteins degradation starts by attaching those proteins to
polymers of the highly conserved Ub protein which are firstly activated by Ub-
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activating enzyme E1. This covalent modification targets the conjugated protein to the
26S proteasome, a protease complex. The attachment of Ub commonly occur on
Lysine side chain of the protein. The activated Ub is then transferred to the active site
Cystine residue in the second protein, an E2 Ub-conjugating enzyme. With the aid of
Ub-protein ligase E3, E2 catalyzes the ligation of the polyubiquitin chain onto the
protein that is destined for degradation. The polyubiquitinated substrate can bind
directly to the Ub receptors in the 26S proteasome or to adaptor proteins that contain
polyubiquitin-binding domain and proteasome-binding domain. After binding, protein
unfolding occurs and the polyubiquitin chain is removed by proteasome-associated deubiquitylating enzymes (DUBs). DUBs is important in maintaining a sufficient pool
of free Ub molecules inside the cell and they translocate the unfolded protein to the
central proteolytic chamber, where the targeted protein will be cleaved into shorter
peptides [76, 78, 79].
1.4.3.2 Spatial control of proteolysis
Some substrates are only recognized at particular locations in the cell by the
UPS. This is because the UPS components localize to specific places in the cell, or it
is because the substrates can only be modified in a specific compartment. Localized
proteolysis is difficult to be measured directly, therefore, in most cases spatial control
is inferred from the localizations of substrate and UPS constituents. E3 are most often
localized to distinct subcellular structures or compartments; E1, Ub, most E2s and the
proteasomes are more uniformly distributed. Evidence also indicates that the E3s carry
out the rate-limiting step in Ub-mediated proteolysis and may bind and recruit
proteasomes to the substrate. Therefore, analyzing E3 behavior should provide insights
into how the proteolysis of substrates is controlled [80].

18
1.4.4 Metastasis
At early stages of tumor progression, cancer cells multiply near the site of
origin; this results in a primary tumor where cancer cells proliferate and expand within
the organ of origin. These primary tumors correspond approximately to 10% of cancer
deaths, while the remaining 90% of deaths were found in patients that have
metastasized tumors. Metastasis is the process by which tumor cells from a primary site
invade and migrate to other parts of the body [5, 81].
Cell migration depends on the type of malignant tumor and the neighboring
tissue and is defined by distinct patterns in the activity of extracellular proteases,
matrix-cell adhesion mediated by integrins, cell-cell adhesion mediated by cadherins,
cellular polarity and cytoskeletal arrangements [82].
Tumor cells undergo major steps during metastasis which are invasion,
intravasation, transport through the blood stream, extravasation and metastatic
colonization [8]. Therefore, better understanding of the molecular mechanisms of
metastasis is important to develop new treatments and prevention strategies against
cancer.
1.4.4.1 Invasion
Invasive ability of cancer cells is considered as key features of metastatic
cascade. In order for cells of primary tumor to invade surrounding tissue, they must
escape from the normal molecular restrictions that link nearby cells to each other. Thus,
these tumors cells need to remodel their cell-matrix and cell-cell adhesion interactions
to gain invasive capabilities [5]. This occur through Epithelial–mesenchymal
transition (EMT) which is a reversible cellular process that converts epithelial cells
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into mesenchymal cell transiently [83]. During EMT, epithelial cells progressively
lose their brick epithelial shape in monolayer cultures and convert into a spindleshaped, mesenchymal morphology cells. Remodeling of cell–cell and cell–
extracellular matrix (ECM) interactions occur during EMT, which leads to the
detachment of epithelial cells from each other and the underlying basement membrane
and their migration by activating a new transcriptional program [84, 85]. E-cadherins
are cell adhesion molecules that are crucial to hold epithelial cells together through
tight junctions. When EMT is activated, the expression of E- cadherin is repressed,
which leads to the loss of the typical epithelial morphology. The cells acquire a
spindle- shaped mesenchymal morphology and express markers such as N- cadherin,
vimentin and fibronectin which are associated with the mesenchymal cell state [84].
Invasion of cancer cells into adjacent tissues requires the action of several
hydrolytic enzymes or proteases, which are released either by cells around the tumor
or by the tumor cells themselves [86]. Matrix metalloproteinases (MMPs) and serine
proteases are two families of proteolytic enzymes implicated in metastasis [87]. MMPs
production is induced via a protein named ECM metalloprotease inducer
(EMMPRIN). These MMPs act on degrading the structural components of ECM and
basement membrane and cleave other proteins found outside the cells, such as vascular
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) [ 8 8 ] .
1.4.4.2 Intravasation
To intravasate, tumor cells need to invade the ECM towards blood vessels.
Tumors induce local angiogenesis, and these new blood vessels have weak cell–cell
junctions through which cancer cells can enter the vascular system [89]. Factors such
as transforming growth factor-β (TGFβ) or VEGF, reduce endothelial barrier function;
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thus, increasing the number of cancer cells entering into blood vessels and increase
metastasis [90].
1.4.4.3 Transport
Circulation and transport of tumor cells through the bloodstream and lymphatic
vessels flows in one direction [8]. Upon entering the bloodstream, tumor cells are
exposed to shearing forces and interactions that might cause their destruction.
However, cancer cells are able of resisting this destruction by attaching to the
endothelial cells of blood vessels and thereby protecting themselves from the immune
system [91].
1.4.4.4 Extravasation
The attachment of tumor cells to endothelial cells is the first step of the
extravasation process and is followed by transendothelial migration (TEM). Indeed,
tumor cells do not damage or induce vascular leak at the site of extravasation; however,
they induce local vessel remodeling [92]. Adhesion of tumor cells to the endothelium
requires the expression of ligands and their receptors on tumor cells and endothelial
cells. Ligands and receptors contributing to this process include selectins, integrins,
cadherins, CD44 and immunoglobulin superfamily receptors [93]. Chemokines, as
well, have important roles in regulating extravasation [94].
1.4.4.5 Colonization
During cancer progression, tumor colonization in a secondary organ marks the
difference between a possibly curable tumor and a generally incurable disease [95].
Primary tumor secretes growth factors to direct progenitor hematopoietic cells from
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bone marrow toward the bloodstream to the site of metastasis. By this, a preparation
of a premetastatic microenvironment occurs even before the arrival of the tumor cells
[96, 97]. Steps of metastasis process are depicted in Figure 2.

Figure 2: Schematic diagram of cancer metastasis [98]

1.4.5 Angiogenesis
Like normal organs, tumors also need to have their blood supply to satisfy their
need for nutrients and oxygen and other metabolic functions [99]. This is achieved
through angiogenesis which is the process of developing new blood vessels from a
pre-existing vascular network [100]. The regulation of angiogenesis depends on a net
balance between anti-angiogenic factors and pro-angiogenic factors. However, in
cancer, the balance is tilted toward angiogenic factors to drive vascular growth [101].
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Pro-angiogenic factors involve VEGF, TNF-α and other factors that are secreted from
tumor cells or mobilized from the ECM [8].
1.5 Therapy
Many types of cancer treatment are used -independently or combineddepending on the type of cancer and how advanced it is. Surgery is the most common
type of therapy for colorectal cancer and breast cancer where the tumor alongside with
some of the healthy tissues are removed [8]. Radiation therapy exerts its effect by
damaging DNA of all cells in the body, while healthy cells can repair the damage,
cancer cells will accumulate DNA damage that would eventually be lethal to them [8].
Chemotherapy targets fast dividing cells aiming at inhibiting mitosis and cellular
growth and by that stopping the progression of cancer [8]. Although great
advancements in cancer treatment and control have been achieved, the undesired side
effects that are accompanied by such treatments have serious effects on the health of
the person. Therefore, alternative therapies that include less toxic and more potent
anticancer drug are needed to be developed [102, 103].

1.5.1 Targeted therapy
Targeted therapy refers to major modalities of medical treatment that block the
growth and metastasis of cancer by targeting specific molecules that are critical for
cancer growth and survival. Different from traditional chemotherapy, targeted therapy
focuses on molecular abnormalities specific to cancer which make it more effective
than chemotherapy and radiotherapy and less harmful to normal cells [104]. Targeted
cancer therapy was first recognized in 1998, when trastuzumab, a monoclonal antibody
against HER2, was approved by the FDA for treating patients with HER2- positive
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metastatic breast cancer [105]. In 2001, imatinib, which was the first designed smallmolecule inhibitor that targets constitutively activated Bcr-Abl, was approved for the
treatment of chronic myeloid leukemia [106]. Since then, over 30 targeted drugs were
approved for clinical use, either alone or in combination with chemotherapy for
treating different human cancers which made a revolution in anti-cancer drug
development [104]. Nonetheless, targeted therapy remains challenged because of the
extremely small proportion of patients that can benefit from it and the high failure.
1.5.2 Plant therapy
For thousands of years, mankind looked to plants for utilizing their medicine.
Plants were used starting from the leaves to the roots, and they were extracted as crude
extracts such as tinctures, teas, powders and other forms of formulations. The use of
plants for medicinal purposes kept evolving throughout history, in the early 19th
century active compounds were isolated and purified, beginning with the purification
of morphine from opium. Medicinal plants are a rich source of a wide variety of active
compounds referred to phytochemicals which can offer a lot of possibilities in the
development of drugs to treat several diseases including cancer [103, 107].
An ideal phytochemical is one that possesses anti-tumor properties with
minimal or no toxicity and has a defined mechanism of action. Hence, identification
and development of new chemotherapeutic agents from plants have gained significant
recognition in the field of cancer therapy and become a major area of experimental
cancer research especially in developed countries where they have considerably
improved quality of the herbal medicines used in the treatment of cancer. Recently,
scientists all over the world are concentrating on the herbal medicines to fight
against cancer [108].
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Moreover, plant derived drugs have been used in cancer treatment such as
Taxol that is isolated from the bark of Taxus brevifolia Nutt [109], Camptothecin
isolated from the Chinese Camptotheca acuminata Decne [110], Combretastatin
isolated from Combretum caffrum [111] and Vinblastine and Vincristine that are
isolated from Catharanthus roseus [112]. Several other types of promising bioactive
compounds of plant origin are currently in clinical trials or preclinical trials or
undergoing further investigation [113].
By understanding the complex synergistic interaction of various constituents
of anti-cancer herbs, new novel herbal anti-cancer agents can be discovered and
designed to attack the cancerous cells without affecting normal cells of the body.
1.5.2.1 Rhus coriaria
Rhus coriaria, which is commonly known as sumac, is a Mediterranean
shrub that belongs to the Anacardiaceae family and traditionally has been used as a
spices and flavoring agents [114]. Sumac is a shrub with height range of 3-4 meters,
pinnate leaves are in pairs of 6 or 8 small leaflet, and with cluster of white flowers
in terminal. The fruits are spherical and become reddish drupe when ripe [115].
1.5.2.1.1 Chemical composition of Rhus coriaria
Rhus coriaria plant is rich in phytochemical compounds. This was identified
through many studies that were conducted in order to identify the chemical
compounds present in Rhus coriaria plant in a process to link them to different
biological activities. One of the earliest researches conducted on this matter was in
1896 when Perken et al., identified myricetin as the coloring agent which was
detected in the extract leaves of the Italian sumac and they identified gallic acid to
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be present in the extract as well [116]. Since then, researchers continued on this road
by investigating the other chemical compositions of different parts of the sumac
organs. This was up to 2014 when Abu-Reidah et al., carried out a comprehensive
study to investigate the phytochemical components of the sumac fruit extract. They
identified 211 phenolic and other phyto-constituents, most of which have been
described for the first time in Rhus coriaria fruits [117].
1.5.2.1.2 Biological activities of Rhus coriaria
Rhus coriaria plant has therapeutic values and also has been used as a
traditional medicine for hundreds of years which attract more attention to it recently.
The biological activities of Rhus coriaria are often attributed to their vital
compounds, these exhibited activities can be a result of the contribution of different
compounds at once or the reaction of one compound only. It has been established
that Rhus coriaria has many biological properties such as anti-bacterial activities
[118, 119], anti-diabetic activities [120], anti-fungal activities[121], anti-oxidant
activities [122, 123], cardioprotective activities [124-126], anti-nociceptive
activities [127], neuroprotective activities [128-131] and dental protection activities
[132, 133].
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Chapter 2: Objectives
We have recently shown that ethanolic extract of Rhus coriaria extract
(RCE) induces cell cycle arrest along with concomitant autophagic cell death of
TNBC cells. However, whether it can modulate the metastatic phenotype of these
cells remained largely obscure. Here, we sought to determine the effect of RCE on
the malignant behavior of MDA-MB-231 breast cancer cells and determine the
underlying mechanisms. Moreover, we extended our study and investigated the anticancer effect of RCE on HT-29 and Caco-2 human colorectal cancer cells.

The hypotheses of this work are stated as the following:

Hypothesis 1: RCE might inhibits breast cancer cell metastasis.

Hypothesis 2: RCE might exerts anti-cancer activities against colorectal cancer.
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Chapter 3: Materials and Methods
3.1 Cell culture and reagents
Human breast cancer cells MDA-MB-231 and Human colorectal cancer cells
HT-29 and Caco-2 were maintained in DMEM (Hyclone, Cramlington, UK). Media
were supplemented with 10% fetal bovine serum (FBS) (Hyclone, Cramlington,
UK), 100 U/ml penicillin/streptomycin (Hyclone, Cramlington, UK). MG-132 was
obtained from Cell Signaling, 3-Methyl adenine (3-MA) from Millipore (Hayward,
CA, USA) and Chloroquine (CQ) from Sigma-Aldrich (Saint-Quentin Fallavier,
France).
Antibodies to NF-κ B, phospho-p65, Flottilin-2, p62/SQSTMI, cleaved PARP
and TNF-α were obtained from Abcam (Cambridge, UK). Antibodies to P300, STAT3,
pSTAT3, β-actin, goat anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP were
obtained from Santa Cruz Biotechnology, Inc (California, USA). Antibodies against
LC3, ATG5, ATG7, P27, AKT, Beclin-1, Rab9, Ubiquitin, mTOR, phospho-mTOR
(Ser 2448), caspase-3, caspase-7, p53, Beclin-1 and control siRNA were obtained from
Cell Signaling (Massachusetts, USA). Those against cleaved caspase 3, Cyclin D1,
HIF-1α, Acetyl H3, Acetyl H4, and phospho-AKT (Ser 473) were obtained from
Millipore (Hayward, CA, USA). Antibody against PARP (full-length and cleaved) was
purchased from BD Pharmingen (New jersey, USA).
3.2 Preparation of the RCE
Fruits of Rhus coriaria were collected from a private farm located in
Ma’rakeh, Tyre, Lebanon after the approval of its owner. The plant is neither
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endangered nor protected by any laws and it is readily and commercially available
in the market. Ten grams of the dried fruit of Rhu coriaria were ground to a fine
powder. The powder was then suspended in 100 mL of 70% ethanol and the mixture
was kept in the dark for 72 h at 4 °C. Then, the mixture was then filtered, and the
filtrate was evaporated to dryness at room temperature. The red residue was kept
under vacuum for 2–3 h and its mass was recorded. The residue was stored at −20 °C
until further use.
3.3 Matrigel invasion assay
To test invasion in MDA-MB-231 cells, BD matrigel Invasion Chamber (8μ m pore size; BD Biosciences, Bedfrord, MA, USA) was used according to
manufacturer’s instructions. In brief, MDA-MB-231 cells (1 × 105 /well) were
placed in 0.5 mL of media that contains 0.2% ethanol as control or RCE (
200µg/mL) and then were seeded into the upper chambers of the system; while the
bottom wells were filled with media supplemented with 10% FBS as a chemoattractant and then incubated at 37 °C for 24 h. Non-penetrating cells were removed
from the upper surface of the filter. Cells that have migrated though the matrigel
were fixed with 4% formaldehyde and stained with DAPI nuclear stain. DAPI
fluorescence was detected by a filter with excitation wavelength of 330–380 nm and
barrier filter of 400 nm. Stained nuclei were counted in 10 random fields per well
using inverted fluorescence microscope (Nikon Ti-U, Nikon) at X200
magnification. For quantification, the assay was done in duplicates and repeated
three times.
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3.4 Wound healing migration assay
MDA-MB-231 cells were grown in six-well plates until they reached
confluency. A scratch was done through the confluent monolayer with a sterile
plastic pipette tip. For each sample, three wounds were made. Then, the plates were
washed with 1XPBS and incubated at 37 °C in fresh DMEM supplemented with
10% FBS in the presence of ethanol or different concentrations of RCE. Three
arbitrary places were marked where the width of the wound was photographed with
an inverted microscope (Nikon Ti-U, Nikon) at X40 magnification. The closure of
the wound was determined by measuring the distance (μm) between the edges of the
wound at time 0, 6 and 10 h, using the NIS-Elements BR 3.0 software (Nikon).
Quantification of the distance migrated by the cells was done as follow: D = (Size
of the wound at t = 0 h –size of the wound at t = 6 or 10 h).
3.5 Adhesion to fibronectin assay
96-well plates were coated with fibronectin that was dissolved in 1X PBS
and incubated at 37 °C overnight. After that, plates were blocked with 3% BSA for
3 h at room temperature. MDA-MB-231 cells at density of 5 × 103/well were then
seeded in growth medium and incubated for 60 minutes in the humidified incubator.
Cells were then washed 1X PBS to remove non-adherent cells. Attached cells were
stained with 1% crystal violet and observed under the microscope. At least five
random fields were counted, and the experiment was repeated three times.
3.6 Measurement MMP-9 by ELISA
Cells were seeded in 6-well plates in the presence of 0.2% ethanol or
different concentrations of RCE for 24 h. The conditioned medium was collected
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and the levels of secreted MMP-9 were determined using immunoassay kits
(Abcam, Cambridge, UK) according to the manufacturer’s protocol. The optical
density at 450 nm of each sample was measured using an AMP Platos R 496
microplate reader (AMP Diagnostics, Poland). The proteins present in the
conditioned media were concentrated using the Amicon Ultra-15 protein
purification and concentration column (Millipore, USA) and protein concentration
was assayed using the BCA protein assay kit (Thermo Scientific, USA). Levels of
MMP-9 were normalized to the total protein level in each sample. The assays were
performed in triplicates and three independent experiments were performed. Data
are presented as mean values ± SEM.
3.7 Transient transfection assay
MDA-MB-231 cells (1.5 × 105/well) were seeded in 12-well plates the day
before transfection. Cells were then transfected with the pGL4.32[luc2P/NFκBRE/Hygro] expression plasmid using Fugene HD according to the manufacturer’s
instructions (Promega, Madison, WI, USA). Briefly, 18 h post-transfection, cells
were incubated for another 24 h in fresh complete media containing increasing
concentrations of RCE. Luciferase activity was measured using Dual Luciferase
Reporter Assay System (Promega, Madison, WI, USA). Renilla luciferase reporter
was used as an internal control, to which firefly luciferase values were normalized.
Experiments were repeated three times and the average of three means is
represented ± SEM.
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3.8 Quantitative immunoassay for VEGF
Cells (1.5 × 105/well) were seeded in 24-well plates overnight in serumcontaining culture media and then, the media was replaced by serum-free media.
Cells were treated with vehicle (ethanol) or indicated concentrations of RCE, and
the conditioned media was collected at 24 h. The level of VEGF therein was
measured using a VEGF enzyme-linked immunosorbent assay kit (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s protocol. The optical
density at 570 nm of each sample was measured using an AMP Platos R 496
microplate reader (AMP Diagnostics, Poland). The proteins present in the
conditioned media were concentrated using the Amicon Ultra-0.5 protein
purification and concentration column (Millipore, USA) and protein concentration
was assayed using the BCA protein assay kit (Thermo Scientific, USA). Levels of
VEGF were normalized to the total protein level in each sample. The assays were
performed in triplicates and three independent experiments were performed. Data
are presented as mean values ± SEM.
3.9 ELISA quantification of IL-6
Cells (2 × 105/well) were cultured in a 6-well plate overnight and then serumstarved for 24 h in the presence of vehicle (ethanol) or indicated concentrations of
RCE. Levels of IL-6 in the collected media were measured using ELISA
quantification kit (R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions. The optical density of each sample was measured using
an AMP Platos R 496 microplate reader (AMP Diagnostics, Poland). The proteins
present in the conditioned media were concentrated using the Amicon Ultra-0.5
protein purification and concentration column (Millipore, USA) and protein
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concentration was assayed using the BCA protein assay kit (Thermo Scientific,
USA). Levels of the IL-6 were normalized to the total protein level in each sample.
Assays were performed in triplicates and three independent experiments were
performed. Data are presented as mean values ± SEM.
3.10 Measurement of cellular viability
Cells were seeded in triplicate in 96-well plates at a density of 7,000
cells/well. 24 h later, cells were treated with or without various concentrations of
RCE for different durations. Cell viability was measured with the Cell cytotoxicity
assay kit (Abcam, UK) according to the manufacturer’s instructions. The results are
representative of an average of at least 4 independent experiments. Data were
presented as proportional viability (%) by comparing the treated group with the
untreated cells, the viability of which is assumed to be 100%.
Cell viability was also measured with the Muse™ Cell Analyzer (Millipore,
Hayward, CA, USA) using the Muse Count and Viability Kit (Millipore, Hayward,
CA, USA) which differentially stains viable and dead cells based on their
permeability to two DNA binding dyes. Briefly, cells were plated onto 12-well
plates (50 × 104 cells/ well). The day of treatment cells were counted to estimate the
approximate number of cells per well. Following RCE treatment at indicated times,
viable cells were counted using Muse™ Cell Analyzer.
3.11 Colony formation assay
HT-29 cells were seeded in 6-well plate at a density of 2000 cells/well and
allowed to grow for 7 days to form colonies before RCE is added. The growth media
was replenished every 3 days. After 1 week, various concentrations of RCE were
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added in freshly added medium and the colonies were allowed to grow for 5
additional days. Colonies were photomicrographed at day 0 (colonies at day 7), three
days (colonies at day 10) and 5 days (colonies at day 12) using Evos light
microscope. Then, colonies were washed 3 times with PBS, fixed for 15 min with
4% formalin and stained with 0.01% crystal violet for 30 min. Colonies in each well
were counted and their surface area was determined using the imageJ software. The
experiment was carried in triplicate and repeated three times.
3.12 Colony formation assay in soft agar
Assays were performed in six-well plates. The lower (base) layer consisted of
1 ml 2.4% Noble agar. The base layer was overlaid with a second layer consisted of
2.9 ml growth medium, 0.3% Noble agar, and 3 × 104 HT-29 cells. Growth medium
was then added, and plates incubated at 37o C. Cells were allowed to grow to form
colonies for 10 days before RCE was added. At day 13, colonies were treated with or
without RCE (300 and 450 µg/mL) for 5 days. Following treatment, plates were
washed twice with PBS and then colonies were fixed with 10% ice-cold methanol for
10 min and washed once with PBS. Colonies were allowed to stain for 1 h in solution
containing 2% Giemsa. Colonies in each well were counted using the imageJ software.
The experiment was carried in duplicate.
3.13 Detection of autophagic vacuoles
HT-29 cells (2 X 104) were grown in 8 chambers slides (Millipore) followed
by treatment with or without RCE for 24 h. Following treatment cells were washed
and stained for autophagic vacuoles using the autophagy detection kit (Abcam,
Cambridge, UK) according to the manufacturer’s instructions. Fluorescent autophagic
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vacuoles were examined under Olympus fluorescence microscope CKX 53
(Olympus).
3.14 Quantification of apoptosis by annexin V labeling
Apoptosis was examined using the Annexin V & Dead Cell kit (Millipore,
Hayward, CA, USA) according to the manufacturer’s instructions. Briefly, HT-29
cells were treated with or without RCE for 48 h. Detached and adherent cells were
collected and incubated with Annexin V and 7-AAD, a dead cell marker, for 20 min
at room temperature in the dark. The events for live, early and late apoptotic cells
were counted with the Muse™ Cell Analyzer (Millipore, Hayward, CA, USA).
3.15 Quantification of caspase 3/7 activity
HT-29 cells were seeded at a density of 5,000 cells/well into 96-well plate
in triplicate and treated with or without RCE for 48 h. Caspase 3/7 activity was
measured using a luminescent caspase-Glo 3/7 assay kit (Promega Corporation,
Madison, USA) following the manufacturer’s instructions. Briefly, caspase reagents
were added to triplicate 96 wells. The plate was mixed on an orbital shaker and
incubated for 2.5 h at room temperature in the dark. Luminescent signal was
measured using the GloMax Multi-detection System (Promega).
3.16 Immunofluorescence staining
HT-29 cells (2 × 104) were grown on 8 well labteck chamber slide (Becton
Dickinson) for 24 h, then treated with or without RCE for 24 h. Cells were then fixed
in 10% formalin solution (4% paraformaldehyde) (Sigma-Aldrich; Saint-Quentin
Fallavier, France) for 5 min at room temperature followed by permeabilization in
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PBS containing 0.1% Triton X-100 for 5 min at room temperature (RT). Cells were
then washed three times with PBS, blocked with 5% non-fat dry milk in PBS for
30 min at RT and then incubated with the primary antibody diluted in 1% non-fat
dry milk/PBS for 2 h at 37 °C. Following incubation, cells were washed three times
with PBS and incubated for 45 min at RT in the presence of fluorescein-conjugated
secondary antibody diluted at 1:200 in 1% nonfat dry milk/PBS. After washing with
PBS, cells were mounted in Fluoroschield with DAPI (Sigma-Aldrich; SaintQuentin Fallavier, France) and examined under Olympus fluorescence microscope
CKX53 (Olympus).
3.17 Knockdown of Beclin-1
HT-29 cells (250,000) were seeded in 6-well cell culture plate in serumcontaining growth media and allowed to grow to 50% confluency. Then, cells were
transfected with siRNA I (100 nM) using lipofectamine 2000 transfection reagent
(Invitrogen, Life technologies) as described by the manufacturer for 48 h at 37 °C
in 5% CO2 before treatment for 48 h with and without 300 and 450 µg/mL RCE in
fresh complete media.
3.18 RNA extraction and qRT-PCR
Total RNA from vehicle- or RCE-treated HT-29 cells were prepared using
Trizol reagent (Life Technologies, Inc.) as described by the manufacturer. The
expression of specific genes was determined by qRT-PCR using the GoTaq 1-Step
RT-qPCR system (Promega Corporation, Madison, USA) as per the manufacturer’s
instructions. Amplification was carried out on the Stratagene Mx3000 P (Agilent
technology). Briefly, the amplification reaction consisted of 100ng of total RNA
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and 0.2 µM primers in a final volume of 25 µl reaction. GAPDH was used as an
endogenous reference for normalization. Expression levels were calculated by the
comparative cycle threshold method, and normalization to the control was
performed. A minimum of three technical replicates was used for each sample.
Primer sequences are as follow: GAPDH (Forward): 5′-cacccactcctccacctttg-3′;
GAPDH

(Reverse):

5′-ccaccaccctgttgctgtag-3′;

mTOR

(Forward):

5′-

ctgggactcaaatgtgtgcagttc-3′; mTOR (Reverse): 5′-gaacaatagggtgaatgatccggg-3′;
Beclin-1

(Forward):

5′-acagtggacagtttggcaca-3′;

Beclin-1

(Reverse):

5′-

cggcagctccttagatttgt-3; p53 (Forward): 5′-gttccgagagctgaatgagg-3′; p53 (Reverse):
5′-ttatggcgggaggtagactg-3′.
3.19 Whole cell extract and Western blotting analysis
Cells (2× 106) were seeded in 10 cm culture dishes and cultured for 24 h
before treatment. After incubation with RCE for the indicated time, cells were
washed twice with ice-cold PBS, scraped, pelleted and lysed in RIPA (Pierce) buffer
supplemented with protease inhibitor cocktail and phosphatase inhibitor (Roche).
After incubation for 30 min on ice, cell lysates were centrifuged at 14,000 rpm for
20 min at 4 °C. Protein concentration of lysates was determined by BCA protein
assay kit (Thermo Scientific). Aliquots of 25 µg of total cell lysate were resolved
onto 6–15% SDS-PAGE along with PageRuler Plus Prestained Protein Ladder
(Thermo Scientific). Proteins were transferred to nitrocellulose membranes
(Thermo Scientific) and blocked for 1 hour at room temperature with 5% non-fat
dry milk in TBST (TBS and 0.05% Tween 20). Incubation with specific primary
antibodies was performed in blocking buffer overnight at 4 °C. Horseradish
peroxidase-conjugated anti-IgG was used as secondary antibody. Immunoreactive
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bands were detected by ECL chemiluminescent substrate (Thermo Scientific) and
chemiluminescence was detected using the LiCOR C-DiGit blot scanner. Where
needed, membranes were stripped in Restore Western blot stripping buffer per the
manufacturer’s instructions. Protein quantification was carried out using the ImageJ
software.
3.20 Statistical analysis
Statistical analysis was done using SPSS version 21. Data were reported as
group mean ± SEM. The data were analyzed via one-way ANOVA followed by
LSD’s Post-Hoc multiple comparison test. (*** p < 0.001, ** p < 0.01, and * p <
0.05 indicate a significant difference).
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Chapter 4: Results
4.1 The effect of RCE on breast cancer
4.1.1 RCE induces autophagy that is independent of ATG5 and ATG7
Previously RCE was investigated for the first time for its activity against
triple negative MDA-MB-231 breast cancer cell line. It was reported that RCE
inhibited the viability of MDA-MB-231 cells and induced senescence in those cells.
Moreover, it induced autophagy which was the main cellular death mechanism. To
investigate more into the mechanism of autophagy, the expression of ATG5 and
ATG7 proteins -which are known autophagy marker- were assessed. We found that
RCE induced autophagy independently of ATG5 and ATG7 proteins, as Figure 3
shows a decrease in the expression level of ATG5 and ATG7 proteins.

Figure 3: Western blot analysis of ATG5 and ATG7 in MDA-MB-231. Cells were
treated with increasing concentrations of RCE (100, 200, 400 and 600 μg/mL) for 48 h.

Next, we checked the level of Rab9 which has been connected with the
formation of autophagosomes. Our results showed that Rab9 expression increased
upon RCE treatment.
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Figure 4: Western blot analysis of Rab9 in MDA-MB-231. Cells were treated with
increasing concentrations of RCE (100, 200, 400 and 600 μg/mL) for 48 h.

4.1.2 RCE inhibits the acetylation of Histone 3 and Histone 4 variants
In an attempt to understand the mechanism by which RCE is affecting gene
expression, the status of acetylated H3 and H4 histone variants was assessed, since
impairment in acetylation status has been linked to cancer development and inhibition
of acetylation was a cancer treatment target. Fortunately, we found that RCE caused a
decrease in the acetylation profile of both H3 and H4 proteins (Figure 5).

Figure 5: Western blot analysis of Acetyl H3 and Acetyl H4 in MDA-MB-231. Cells
were treated with increasing concentrations of RCE (100, 200, 400 and 600 μg/mL)
for 48 h.

P300 is a Histone Acetyl Transferase (HAT) enzyme that is known to acetylate
H3 and H4 histone variants. Scoring for P300 showed a decrease in its expression level
upon RCE treatment (Figure 6).
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Figure 6: Western blot analysis of P300 in MDA-MB-231. Cells were treated with
increasing concentrations of RCE (100, 200, 400 and 600 μg/mL) for 48 h.

4.1.3 RCE inhibits the migration ability of MDA-MB-231 cells
Cell migration plays an important role in metastasis; therefore, we tested the
effect of RCE on migration of MDA-MB-231 cells using wound-healing migration
assay. Non-cytotoxic concentrations (100 μg/mL and 200 μg/mL) of RCE were used
to rule out the possibility that migration inhibition is due to cell death (Figure 7).

Figure 7: Cell viability for MDA-MB-231 cells after treatment with RCE.

After reaching their confluency, a wound was created in MDA-MB-231 cells
by scratching using a pipette tip and the cells were incubated in DMEM
supplemented with 10% FBS with control and indicated concentrations of RCE.
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Figure 8 A and B shows that RCE treatment reduced migration upon increasing RCE
concentrations.

Figure 8: RCE inhibited the migration of MDA-MB-231 cells using wound healing
assay. (A) The wound was measured with an inverted microscope at X40
magnification. (B) Values represent the mean ± SEM distance (μm) that cells have
migrated in 6 and 10 h. Data are representative of three independent experiments.
(*p < 0.05, **p < 0.005, ***p < 0.001).
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4.1.4 RCE reduces invasion, downregulates MMP-9 and decreases the adhesion
to fibronectin
Then, we tested the effect of RCE on MDA-MB-231 cells invasion using
matrigel-coated Boyden chamber in the presence of ethanol and different
concentrations of RCE. The number of cells that passed the matrigel coated membrane
was reduced in RCE treated cells, which shows that RCE inhibits the invasive ability
of MDA-MB-231 cells efficiently.

Figure 9: RCE inhibited the invasion potential of MDA MB-231 cells. (A) MDA-MB231 cells were incubated for 24 h with or without RCE. Cells that invaded into the
matrigel were scored. Invaded cells were stained with DAPI and were photographed
at X100 magnification under an inverted microscope. (B) Quantification of invaded
MDA-MB-231 into the matrigel. Values represented in percent were calculated from
three independent experiments and are represented as mean ± SEM. (***p < 0.001).
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Matrix metalloproteinase-9 (MMP-9), plays an important role in breast cancer
cell invasion and metastasis. To test the effect of RCE on breast cancer invasion
through the expression of MMP-9, we examined the expression level of MMP-9 in
conditioned media on MDA-MB-231 cells treated with RCE. We found that secreted
MMP-9 was reduced in response RCE treatment (Figure 10).

Figure 10: Effect of RCE on the secretion of MMP-9 in RCE-treated MDA-MB-231
cells. The levels of secreted MMP-9 was determined using immunoassay kits.
Experiments were repeated three times in triplicate and the average of three means is
represented ± SEM. (***p < 0.001).

Cell transport and adhesion to components of ECM, such as fibronectin, and to
the basement membrane represent an important event in tumor invasion and
metastasis. Thus, we examined the ability of MDA-MB-231 to adhere to fibronectin
in RCE treated cells. We found that RCE inhibited the adhesion of MDA-MB-231
cells to fibronectin (Figure 11 A, B). This effect was very fast as it appeared within
the first 60 min of contact, at time at which no cell death occurred.
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Figure 11: RCE inhibits adhesion of MDA-MB-231 cells to fibronectin. A) Effects of
RCE on MDA-MB-231 cells adhesion to wells coated with fibronectin. MDA-MB231 cells were seeded on the fibronectin-coated wells in the presence or absence of
RCE. Attached cells were stained with crystal violet and photographed with an
inverted microscope at X100 magnification. (B) Quantification of attached MDA-MB231 cells to fibronectin. The number of adherent MDA-MB-231 cells to fibronectin
was determined by counting at least 5 random fields per well at X200 magnification
with an inverted microscope. Data represent a mean of cells counted and are
representative of three independent experiments. (***p < 0.001).

4.1.5 RCE suppresses VEGF production in MDA-MB-231 cells
Cancer growth and metastasis depend on angiogenesis; thus, inhibiting
angiogenesis would inhibit tumor expansion. VEGF which is a pro-angiogenic growth
factor has a crucial role in angiogenesis. Therefore, we checked the effect of RCE on
VEGF production by MDA-MB-231 cells. Figure 12 shows that treatment with RCE
reduced VEGF secretion by MDA-MB-231 cells.
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Figure 12: Reduced VEGF secretion in RCE-treated MDA-MB-231 cells.
Quantification of basal level of VEGF secretion. MDA-MB-231 cells were treated
with vehicle or the indicated concentrations of RCE for 24 h and then secreted VEGF,
in the conditioned medium, was analyzed by ELISA. Data represents means ± SEM of
three independent experiments. (*p < 0.05, **p < 0.005).

4.1.6 RCE downregulates the expression of TNF-α and reduces IL-6 production
in MDA-MB-231 cells
Several studies had reported that the cytokine TNF-α is involved in cancer cell
migration and invasion in different cancer types including breast cancer. Therefore,
TNF-α might be considered as a therapeutic target for breast cancer treatment. Since
we found that RCE reduced cell MDA-MB-231 cells migration and invasion, we
examined the effect of RCE on TNF-α protein expression. Figure 13 shows that RCE
induced a reduction in TNF-α protein expression in MDA-MB-231 cells.

Figure 13: Western blot quantification showing a decrease in TNF-α protein in RCEtreated MDA-MB-231 cells.
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After that, we tested the level of IL-6 which is another cytokine that is produced
by breast cancer cells and has been shown to increase proliferation and metastasis in
breast cancer cells. We found that RCE reduced the level of IL-6 in MDA-MB-231
cells (Figure 14).

Figure 14: Reduction of IL-6 production in MDA-MB-231 cells. IL-6 production was
quantified by ELISA. Data represents means ± SEM of three independent experiments.
(*p < 0.05).
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4.1.7 RCE attenuates STAT3 activation and inhibits NFκB pathway in MDAMB-231 cells
STAT3 is a transcription factor that is activated by phosphorylation and is
considered to be a mediator of tumorigenesis since it is involved in promoting cellular
proliferation, resistance to apoptosis, invasion and migration of cancer cells [134].
Therefore, STAT3 is recognized as a potential target for cancer treatment. For that
reason, we analyzed the level of pSTAT3 in MDA-MB-231 cells treated with RCE.
We found that the phosphorylation of STAT3 was reduced upon RCE treatment
(Figure 15).

Figure 15: Concentration-dependent decrease of phospho-STAT3 in RCE-treated
MDA-MB-231 cells.

NFκB signaling pathway is known to regulate the expression of different genes
involved in cancer cells invasion. Therefore, we first examined the status of phosphop65 in RCE-treated MDA-MB-231 cells. We found that RCE inhibited the p65
phosphorylation (Figure 16 A). After that, we measured the ability of RCE to inhibit
the transcriptional activity of NFκB. Therefore, MDA-MB-231 cells were transfected
transiently with an NFκB reporter expression vector. Figure 16 B showed that RCE
repressed NFκB-dependent transcription of the luciferase reporter.
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Figure 16: Inhibition of the NFκB signaling pathway by RCE. A) Western blot analysis
showed a decrease of phospho-p65 (NFκB) in MDA-MB-231 cells in response to RCE
treatment. (B) Inhibition, by RCE, of NFκB transcriptional activity in MDA-MB-231
cells. MDA-MB-231 cells were transfected with the pGL4.32[luc2P/NFκBRE/Hygro] expression plasmid and luciferase activity were measured 18 h posttransfection. Columns represents mean; bars represent SEM of three independent
experiments. (*p < 0.05, **p < 0.005).

4.1.8 RCE downregulates Flotillin-2 and HIF-1a
Flotillin-2 is a major scaffold protein on lipid rafts which was initially
identified as a protein that was upregulated during axon regeneration after optic nerve
lesion. Studies shown that dysregulation in Flotillin-2 protein contributed to the
formation of cancer-specific cellular characteristics and was closely associated with
tumor development, invasion, and metastasis [135]. For that reason, the expression of
Flotillin-2 was assessed after treatment with RCE. Results indicated that RCE caused
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a decrease in Flotillin-2 level (Figure 17) which can be used as a treatment target since
studies had shown that Flotillin-2 was upregulated in breast cancer patients.

Figure 17: Western blot analysis showing a concentration-dependent decrease of
Flotillin-2 in MDA-MB-231 cells in response to RCE treatment.

Hypoxia-inducible factor-1(HIF-1) has been recognized as an important cancer
drug target. It has been shown that elevated levels of HIF-1 was associated with tumor
metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy.
Hypoxia is a common characteristic in many types of solid tumors. As an adaptive
response to hypoxic stress, hypoxic tumor cells activate several survival pathways to
carry out their essential biological processes one of which HIF-1α pathway which is
considered as a crucial survival pathway for novel strategies of cancer therapy to be
developed [136]. Therefore, the level of HIF-1α protein was examined upon RCE
treatment and it was found that HIF-1α decreased in a concentration- dependent
manner.

Figure 18: Western blot analysis showing a concentration-dependent decrease of
HIF-1α in MDA-MB-231 cells in response to RCE treatment.
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4.2 The effect of RCE on colon cancer
4.2.1 RCE inhibited the cellular viability of HT-29 and Caco-2 colon cancer cells
RCE at first was tested for its anti-colon cancer effect on the viability of HT29 and Caco-2 (Figure 19 A and B) using an assay that monitor the cell metabolic
activity. Exposure of HT-29 or Caco-2 cells to RCE decreased cellular viability in
a time and concentration-dependent manner. The calculated IC50 values for the HT29 cells were 518 µg/mL at 24, 346 µg/mL at 48 and 271 µg/mL at 72 h. While
Caco-2 cells has IC50 of 384 µg/mL at 24 and 316 µg/mL at 48 h, respectively.

Figure 19: Inhibition of cellular viability by RCE. (A) Exponentially growing HT-29
and (B) Caco-2 colon cancer cells were treated with and without the indicated
concentrations of RCE. Data represent the mean of six independent experiments
carried out in triplicate. (**p < 0.005, ***p < 0.001).
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Cell viability was tested using an assay that differentially stains viable and
non-viable cells based on their permeability to two DNA binding dyes. We found
that there was a decline in the number of viable HT-29 cells upon RCE treatment
which indicate that cell death occurred, when comparing them to the number of cells
counted at the day 0 which is the day of treatment (Figure 20).

Figure 20: Determination of cellular viability through cell counting. HT-29 cells were
exposed to RCE for 24 h and 48 and cell viability was monitored using the Muse
cell analyzer. Data represent the mean ± SEM of three independent experiments.

Observation of HT-29 (Figure 21 A) and Caco-2 (Figure 21 B) cells upon
RCE treatment using light microscopy showed morphological changes in both cell
lines compared to control cells. Actually, a subpopulation of HT-29 and Caco-2
cells treated with RCE showed cytoplasmic vacuolation (dashed arrows). Higher
concentrations of RCE (600 µg/mL), showed a subpopulation of cells that appeared
smaller and rounded, which is a characteristic of dying cells (arrowheads).
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Figure 21: RCE induced morphological changes on human (A) HT-29 and (B) Caco2 colon cancer cells using EVOS XL Core Cell Imaging System at X40.
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4.2.2 RCE inhibits HT-29 colony growth
To further confirm the anti-cancer potential of RCE, we wanted to test the
effect of RCE on the proliferative capacity of HT-29 colonies formed in culture. For
that, HT-29 cells were grown for seven days to form colonies and then treated for
five days with different concentrations of RCE. Figure 22 A and B showed that RCE
treatment caused a significant decrease in the number and size of colonies in a
concentration dependent manner. This significant reduction in number and size of
colonies is clearly indicative of massive cell death. Additionally, microscopic
observation of the treated colonies showed cellular vacuolation which suggest
autophagy induction.
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Figure 22: RCE inhibits HT-29 colony growth. (A) HT-29 colonies were first allowed
to form in normal media for seven days. Formed colonies were then treated with or
without different concentrations of RCE and allowed to grow for five more days
before crystal violet staining. Size and morphology of the growing colonies were
followed over time under the microscope at X40 magnification. (B) Inhibition of
colony growth was assessed by measuring the number and size (surface area) of the
colonies obtained in control and RCE-treated plate. Data represent the mean of three
independent experiments carried out in triplicate. (*p < 0.05, **p < 0.005).
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Colony formation by HT-29 was also done using soft agar colony formation
assay. Similarly, RCE markedly reduced the number of colonies when grown on
soft agar (Figure 23 A and B).

RCE (µg/mL)

Figure 23: RCE inhibits HT-29 colony growth in soft agar. HT-29 colonies were first
allowed to form in normal media for 13 days. Formed colonies (A) were then treated
with or without RCE at the indicated concentrations and allowed to grow for 5 more
days before staining. Inhibition of growth was assessed by measuring the size of the
colonies in control and RCE-treated plate.

4.2.3 RCE induces Beclin-1 independent autophagy
We have shown in the previous results that RCE induced morphological
changes in HT-29 and Caco-2 colon cancer cells (Figure 21) indicated by the
massive cytoplasmic vacuolation which suggest the induction of autophagy (dashed
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arrows). To confirm the autophagic origin of those vacuoles, a fluorescence marker
of autophagy vacuoles was used. Figure 24 showed that exposure of HT-29 cells to
RCE for 24 h led to an accumulation of autophagic vacuoles, thus confirming the
induction of autophagy by RCE in colon cancer cells.

Figure 24: RCE induced the formation of autophagic vacuoles in HT-29. HT-29 cells
were seeded in 8 chambers slide followed by treatment with or without 450 µg/mL
RCE. Following treatment cells were washed and stained for autophagic vacuoles.
Fluorescent autophagic vacuoles were examined under Olympus CKX54
fluorescence microscope.

After that the protein expression of specific markers for autophagy were
examined. As described earlier, the conversion of LC3-I into LC3-II is a key
characteristic in autophagy, therefore, we analyzed the accumulation of LC3-II by
Western blotting. Figure 25 A shows that RCE induced an accumulation of LC3-II
starting at 300 µg/mL of RCE in HT-29 Cells. Similarly, RCE also induced an
accumulation of the LC3-II in Caco-2 cells (Figure 25 A). Moreover,
immunofluorescence staining for endogenous LC3B revealed clear LC3-positive
puncta in RCE treatment in HT-29 cells. Endogenous LC3B was hardly detectable
in control cells (Figure 25 B).
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Figure 25: Detection of LC3-II. (A) Western blotting analysis of LC3-II expression
in RCE-treated HT-29 and Caco-2 cells. (B) Immunofluorescence staining of LC3B
in RCE-treated HT-29 cells. HT-29 cells were treated with RCE (450 µg/mL) for
24 h and then cells were stained with antibody specific for LC3B and DAPI.
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Moreover, the expression p62(SQSTM1) was also evaluated. Figure 26
shows a decrease in p62(SQSTM1) level at 300 µg/mL, suggesting that autophagy
is induced by a concentration ≥300 µg/mL of RCE.

Figure 26: Western blotting analysis of P62 expression in RCE-treated HT-29 cells.

After that, we assessed the expression of Beclin-1, the autophagy effector
that plays a key role in autophagosome formation as described earlier. Surprisingly,
we found that Beclin-1 levels in HT-29 cells decreased after treatment with RCE at
concentration of 300 µg/mL RCE (Figure 27 A). Similarly, Beclin-1 decrease was
also observed in RCE-treated Caco-2 cells starting at 300 µg/mL RCE (Figure 27
A). Beclin-1 protein downregulation was also confirmed by immunofluorescence
staining of Beclin-1 in HT-29 cells treated with 450 µg/mL RCE (Figure 27 B).
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Figure 27: RCE downregulates Beclin-1. (A) Western blotting analysis of Beclin-1
expression in RCE-treated HT-29 and Caco-2 cells. (B) Immunofluorescence
staining of Beclin-1 in RCE-treated HT-29 cells. HT-29 cells were treated with RCE
(450 µg/mL) for 24 h and then cells were stained with antibody specific for Beclin1 and DAPI.
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To confirm that Beclin-1 is not required for the autophagy that is induced by
RCE, beclin-1 protein was knocked down in HT-29 cells using Beclin-1-specific
siRNA. As it is shown in Figure 28, knockdown of Beclin-1 did not inhibit LC3-II
accumulation and hence RCE-induced autophagy.

Figure 28: Western blotting analysis of LC3-II expression after knockdown of Beclin1 using specific siRNA in RCE-treated HT-29 cells.

To investigate the mechanism of Beclin-1 downregulation after RCE
treatment, the level of Beclin-1 transcript was firstly examined in HT-29 cells using
qRT-PCR. As shown in Figure 29 A, the level of Beclin-1 mRNA stayed the same
after RCE treatment which indicate that Beclin-1 downregulation is a
posttranscriptional event. Then, we checked if the downregulation of Beclin-1 is a
result of autophagolysosomal degradation. That was assessed by inhibiting the
autophagolysosome formation using chloroquine (CQ) autophagy inhibitor and then
measuring the level of Beclin-1. As it is shown in Figure 29 B, blocking autophagy
by CQ failed to restore Beclin-1 protein levels after RCE treatment. Moreover,
autophagosome formation inhibition by 3-methyl adenine (3-MA), another
autophagy inhibitor, also failed to restore Beclin-1 protein level (Figure 29 C),
which suggest that downregulation of Beclin-1 is autophagy-independent. Then we
examined the possibility of targeting Beclin-1 for proteasome degradation after
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RCE treatment. For that, cells were first pre-treated with MG-132 (15 µM),
proteasome inhibitor, and then treated with RCE. We found that proteasome
inhibition abrogated the RCE-induced decrease of Beclin-1, whose level remained
comparable to control cells (Figure 29 D). This result clearly indicates that RCE
targets Beclin-1 to proteasome degradation.

Figure 29: RCE targeted Beclin-1 to proteasome degradation in HT-29 cells. (A) qRTPCR showed no effect on the levels of Beclin-1 transcripts. GAPDH was used as
internal normalization control. (B, C) Downregulation of Beclin-1 is autophagyindependent. Cells were pretreated with or without CQ or 3-MA for 1 h then RCE was
added at the indicated concentrations for 48 h. Proteins were extracted and Beclin-1
protein level was determined by Western blot. (D) RCE targets Beclin-1 to proteasome
degradation and inhibitors of the proteasome (MG-132) restore Beclin-1 protein levels.

4.2.4 RCE induces caspase-7-dependent apoptosis in HT-29 cells
Next, we investigated the reason behind the inhibition of cell viability after
RCE treatment and whether it was associated with apoptosis induction. An increase
in the apoptotic populations of HT-29 cells was observed after RCE treatment
starting at 300 µg/mL using Annexin V staining which indicates that these cells
committed apoptosis (Figure 30).
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Figure 30: Induction of apoptosis by RCE in HT-29 cells. Annexin V binding was
carried out using Annexin V & Dead Cell kit. Cells were treated with or without
increasing concentrations of RCE for 48 h. Detached and adherent cells were
collected and stained and then the events for total apoptotic cells were counted with
the MuseTM Cell Analyzer. (**p < 0.005, ***p < 0.001).
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To further confirm apoptosis induction upon RCE treatment in HT-29 cells,
cleaved PARP, a marker of apoptosis, was checked. Figure 38 B showed that RCE
induced a dose-dependent increase in cleaved PARP expression. After that we
assessed the activation of caspase 3/7 using a caspase 3/7 activity assay (Figure 31
A), a significant increase in caspase 3/7 activity was observed after RCE treatment
at concentrations of 300 and 450 µg/mL RCE by 3 and 5 folds, respectively.
Moreover, Western blot analysis showed that RCE caused a decrease in caspase-3
levels. Interestingly, the decrease in the pro-form was not associated with increase
in the processed active form. Based on this result, it appears that apoptosis that is
induced by RCE is independent of caspase-3 activation. This inspired us to assess
the activation of caspase-7. As shown in Figure 31 B, the expression level of cleaved
caspase-7 increased obviously in RCE-treated HT-29 cells, suggesting that RCE
induced a caspase-7- dependent apoptosis in colon cancer.
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B.

Figure 31: Induction of caspase-7-mediated apoptosis by RCE in HT-29 cells. (A)
Stimulation of caspase 3/7 activity in HT-29 cells after exposure to RCE for 48 h. The
relative caspase 3/7 activity was normalized to the number of viable cells and was
expressed as fold of activation compared to the control cells. (*p < 0.05, **p < 0.005)
(B) Western blot analysis of caspase-3, -7 activation and PARP cleavage in RCEtreated HT-29 cells after 48 h treatment.
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4.2.5 Inhibition of autophagy rescues RCE- induced cell death in HT-29 cells
Since RCE induced apoptosis and autophagy, and because those two events
are known to induce cell death, we aimed to investigate the contribution of apoptosis
and autophagy to the viability inhibition activity of RCE. Therefore, we aimed to
determine the timing at which autophagy and apoptosis occurred. For that, timecourse analysis was performed for both events and the induction of autophagy and
apoptosis was monitored over time. HT-29 cells were treated with 450 µg/mL of
RCE and autophagy was detected through the conversion of LC3-I into LC3-II while
apoptosis was examined through PARP cleavage. Autophagy was evident after 12 h
after-treatment (Figure 32, lower panel), on the other hand apoptosis (Figure 32,
upper panel), occurred 48 h after-treatment. These data indicate that autophagy is
an early event that precedes apoptosis induction in response to RCE.

Figure 32: Time-course analysis of PARP cleavage and LC3-II accumulation in RCEtreated HT-29 cells. Cells were treated with 450 μg/mL RCE and proteins were
extracted at the indicated time-points (3, 6, 12, 24 and 48 h).
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Treatment by RCE at concentration of 300 and 450 µg/mL, induced a
significant cell death (~60 and 70% inhibition of cell viability) after 48 h of RCE
treatment (Figure 19 A) while apoptosis accounted for only ~16 and 25% as
determined by Annexin V staining (Figure 30). This observation led us to test if
these two cell death mechanisms are activated independently or if they are linked
together. To answer this question, we tested the effect, of CQ, 3-MA and Z-VADFMK (pan-caspase inhibitor) on cell viability. Blocking autophagy was further
assessed by evident decrease in the conversion of LC3-I to LC3-II by CQ and 3-MA
whereas blocking apoptosis was assessed by the absence of cleaved PARP (Figure
33).

Figure 33: Analysis of LC3-II accumulation in HT-29 cells pre-treated with autophagy
inhibitors (CQ or 3-MA) and pancaspase inhibitor. Proteins were extracted and LC3II accumulation was determined by Western blot. Western blot quantification of
cleaved PARP in cells pretreated with and without pan-caspase inhibitors to confirm
apoptosis.
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Cell viability improved significantly after autophagy inhibition. On the other
hand, inhibition of apoptosis had almost no effect on cell death when compared to
control cells treated with RCE only in HT-29 cells (Figure 34). This result is
unexpected because at RCE concentrations of 300 and 450 µg/mL, apoptosis
accounted for ~ 16 and 25% of cell death, respectively (Figure 30) in HT-29 cells.
Similar result was also obtained with Caco-2 cells (Figure 34).

Figure 34: Inhibition of autophagy but not apoptosis reduces cell death induced by
RCE. HT-29 cells were pretreated with CQ, 3-MA or the pan-caspase inhibitor (ZVAD-FMK) and Caco-2 was pretreated with CQ or the pan-caspase inhibitor (ZVAD-FMK) and then treated for 48 h with 300 or 450 µg/mL RCE.
(**p < 0.005, ***p < 0.001).
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It is also noteworthy to mention that, even though CQ induced PARP cleavage
in control cells, RCE treatment did not lead to a further increase of the level of cleaved
PARP (Figure 35), suggesting that the inhibition of autophagy led to the inhibition of
RCE-induced apoptosis and therefore suggesting that apoptosis induction is
autophagy-dependent.

Figure 35: Western blot of cleaved PARP in cells pretreated with and without
autophagy inhibitor.

4.2.6 RCE induces proteasome-dependent degradation of mTOR, Akt, p53 and
caspase-3 in HT-29 cells
Next, we examined the mechanism through which RCE might exert its
effects on autophagy and apoptosis in particular. mTOR kinase is a downstream
target of the PI3K/AKT signaling pathway and has a role as a negative regulator of
autophagy, was reported to regulate colorectal cancer tumorigenesis [137].
Therefore, we decided to test the effect of RCE on PI3K/AKT/mTOR pathway in
HT-29 cells. For that, we examined the phosphorylation level of mTORC1 at
Ser2448. Treatment with RCE led to a decrease in the level of mTORC1
phosphorylation in HT-29 and Caco-2 cells dramatically, which suggest an
inhibition of mTOR activity upon RCE treatment. Unexpectedly, we observed a
significant decrease in the total mTOR protein level in HT-29 and Caco-2 cells after
RCE treatment. Likewise, a decrease in AKT, upstream regulator of mTOR
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pathway, phosphorylation as well as total AKT protein was observed in HT-29 and
Caco-2 cells treated with RCE (Figure 36).
HT-29 (48 h)

Figure 36: Concentration-dependent decrease of phospho-mTOR, total mTOR,
phospho-AKT and total AKT protein in RCE-treated HT-29 and Caco-2 cells.

Then, we tested if the inhibition of mTOR was at the transcription level.
Toward this qRT-PCR analysis of mTOR was carried on. Figure 37 showed that
mRNA transcript level in HT-29 cells treated with RCE had no significant
difference in mRNA levels compared to the control.

Figure 37: Downregulation of mTOR is transcription-independent. Total RNA from
RCE-treated and untreated cells were amplified by qRT-PCR the mTOR transcripts
using mTOR specific primers. GAPDH was used as internal normalization control.
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Also, blocking late stage autophagy by CQ and early stage autophagy by 3MA (Figure 38) failed to restore mTOR and AKT protein expression levels, which
shows that the decrease of these two protein levels after RCE treatment is not a
result of autophagolysosomal degradation.

Figure 38: RCE-mediated decrease in the protein level of mTOR and AKT is
autophagy-independent. Cells were pretreated with or without CQ or 3-MA for 1 h
and then RCE was added at the indicated concentration for 48 h. Proteins were
extracted and mTOR and AKT protein level was determined by Western blot.

Then, we sought to test if the of the proteasome is involved in the decrease
of mTOR and AKT proteins, therefore, HT-29 cells were first pre-treated with MG132, proteasome inhibitor, and then treated with or without RCE. Results shown in
Figure 39 demonstrates that treatment with MG-132 was able to restore these two
proteins to a level comparable to the control.
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Figure 39: RCE targets mTOR and AKT to proteasome degradation. HT-29 cells were
pre-treated for 1 h with MG-132 prior to treatment with RCE.

Next, we examined protein expression level of mutant p53 in RCE-treated
HT-29 cells. Results in Figure 40 A showed a decrease in the expression of mutant
p53 protein. The observed decrease was not a result of decreased gene expression,
since qRT-PCR analysis showed no change in mRNA level of p53 transcripts
between treated cells and control (Figure 40 B).

Figure 40: RCE reduced the level of p53. (A) Downregulation of p53 in RCE-treated
HT-29 cells. (B) qRT-PCR analysis of p53 transcript in RCE-treated HT-29 cells.
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Interestingly, proteasomal inhibition by MG-132 rescued mutant p53 from
degradation (Figure 41), which suggests that mutant p53 is targeted to proteasomal
degradation by RCE as well.

Figure 41: RCE targets mutant p53 to proteasome degradation. HT-29 cells were pretreated for 1 h with or without MG-132 prior to treatment with RCE.

We showed previously that a downregulation of pro-caspase-3 in RCE
treated cells without increase in the active form (Figure 31). This drove us to
investigate if pro-caspase-3 is targeted to proteasomal degradation. Indeed, we
found proteasomal inhibition by MG-132 restored pro-caspase-3 protein to a level
comparable to control cells (Figure 42), indicating that pro-caspase-3 is also
targeted for proteasomal degradation by RCE.

Figure 42: RCE targets Pro-caspase-3 to proteasome degradation. HT-29 cells were
pre-treated for 1 h with or without MG-132 prior to treatment with RCE.
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4.2.7 The activation of proteasome-mediated proteolysis of mTOR by RCE leads
to the activation of autophagy and subsequent apoptosis in HT-29 cells
To determine the order of events at which autophagy and proteasomal
degradation occurs in HT-29 cells, a time course experiment for protein expression
was conducted. It was found that mTOR and its phosphorylated form were the first
to be downregulated. Actually, the degradation of total mTOR occurred as early as
3 h upon RCE-treatment followed by a decline in its active form which was detected
after 6 h post-treatment (Figure 43). Conversely, AKT levels and its active form,
pro-caspase-3 and p53 proteins expression started to decrease after 12 h post-RCE
treatment (Figure 43). We also found that Beclin-1 downregulation, which occurred
as early as 6 h post-RCE treatment (Figure 43, lower panel), started before
autophagy. Autophagy was triggered after 12 h post-treatment of RCE and that was
determined by LC3-II accumulation (Figure 32). Together these results suggest that
the inactivation of mTOR might serve as a trigger for downstream event
(proteasomal degradation, autophagy and apoptosis) induced by RCE.
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Figure 43: Inactivation of mTOR through proteasome degradation precedes
autophagy. Time-course analysis of phospho-mTOR, total mTOR, phospho-AKT,
total AKT, mutant p53, Beclin-1 and pro-caspase-3 in RCE-treated HT-29 cells.
Cells were treated with 450 μg/mL RCE and proteins were extracted at the indicated
time-points (3, 6, 12, 24 and 48 h).
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To test the above hypothesis, we examined the possibility that the rescued
mTOR

protein

from

proteasomal

degradation,

by

MG-132,

could

be

phosphorylated. As shown in Figure 44 (upper panel), the inhibition of the
proteasomal machinery restored phosphorylated mTOR to a level comparable to the
control. Then we checked if the restoration of the active mTOR has an impact on
autophagy activation and consequently on the induction of apoptosis. Restoration
of phospho-mTOR was associated with a significant decrease in the conversion of
LC3-I to LC3-II (Figure 44, middle panel), and with reduced level of active caspase7 as well (Figure 44, lower panel). To further confirm that autophagy and apoptosis
were blocked, cell viability was measured in cells treated first with MG-132 and
then with RCE.

Figure 44: Inhibition of the proteasome rescue phospho-mTOR and block autophagy
and apoptosis induced by RCE. HT-29 cells were pre-treated for 1 h with or without
MG-132 prior to treatment with RCE.
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Interestingly, cell viability was found to be significantly improved after
proteasomal inhibition (Figure 45).

Figure 45: Inhibition of proteasome reduces cell death induced by RCE. HT-29 cells
were pretreated for 1 h with or without MG-132 prior to treatment with RCE for
48 h. (***p < 0.001).

Recent work showed that mTOR decreased activity increases the overall
protein ubiquitination and degradation by the UPS [138]. This drove us to test if
mTOR inactivation by RCE enhances overall protein ubiquitination. HT-29 cells
were treated with 300 and 450 μg/mL RCE and overall protein ubiquitination profile
was determined. We found that RCE treatment resulted in marked increase in the
total content of ubiquitinated protein (Figure 46). Increase in ubiquitinated protein
profile was also observed in Caco-2 cells (Figure 46).

Caco-2

HT-29
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Figure 46: RCE treatment increases the cellular level of ubiquitinated proteins in HT29 and Caco-2 cells.

Additionally, a time course experiment showed that increased protein
ubiquitination profile might be detected as early as 3 h which also coincides with a
time at which a decrease of mTOR protein was observed (Figure 47).

Figure 47: Time-course analysis of protein ubiquitination in RCE-treated HT-29 cells.
Cells were treated with 450 μg/mL RCE and proteins were extracted at the indicated
time-points (3, 6, 12, 24 and 48 h).
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4.2.8 RCE downregulates cyclin D1 and p27
The earliest known and understood about the function of cyclin D is promoting
cell proliferation as a regulatory partner for CDK4 or CDK6. Moreover, cyclin D1 can
bind to p27 (a tumor suppressor protein that regulates G0 to S phase transitions)
independently of CDK4 or CDK6, which promote cell migration [139]. Interestingly,
we found that cyclin D1 was downregulated as the concentration of RCE increased in
HT-29 cells. Moreover, the level of p27 was also downregulated after RCE treatment
in the same cells (Figure 48 A and B).

Figure 48: Downregulation of (A) cyclin D1 and (B) p27 upon RCE treatment. Cells
were treated with increasing concentrations of RCE (100, 200, 400 and 600 μg/mL)
for 48 h.
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Chapter 5: Discussion
5.1 Breast cancer
In this study, we showed that at non-cytotoxic concentrations of RCE,
migration and invasion were inhibited in MDA-MB-231 cells and their adhesion to
fibronectin was abrogated. Furthermore, we found that RCE reduced VEGF
production in MDA-MB-231 and downregulated MMP-9, TNF-α and IL-6.
Interestingly, our investigation revealed that NFκ B and STAT3 pathways were
inhibited in MDA-MB-231 in response to RCE.
An ever-increasing amount of evidence supports the claim that plants are,
indeed, an essential player in the search for better cancer treatment or even a cure.
Many of these plants or plant-derived drugs are acting through modulating
programmed cell death. Autophagy or as referred to as programmed cell death II is the
process in which subcellular membranes undergo dynamic morphological changes that
lead to the degradation of cellular proteins and cytoplasmic organelles. Thus, plants
present themselves as candidates for cancer thereby, with great potential and
investigating their pharmacological capacity is of impending importance [140].
Autophagy was the main cellular death mechanism induced in MDA-MB-231 TNBC
cell line upon RCE treatment. Autophagy is characterized by the induction of
autophagosomes, which will fuse with the lysosomes to form autolysosomes, and to
degrade the content of the autophagosome [141]. Induction of autophagy results in
recruitment of ATGs to the phagophore assembly site (PAS) to help in the nucleation
of an isolation membrane that forms a cup- shaped structure termed the phagophore.
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ATG5 and ATG7 which are key proteins that are needed in phagophore expansion
during autophagy process [56].
In this study we found that autophagy was induced in MDA-MB-231 cell line
independently of ATG5 and ATG7. Indeed, RCE caused a decreased in ATG5 and
ATG7 accompanied with an increase in Rab9 level. These results are in agree with
Nishida et. al., group who showed that mouse cells lacking ATG5 or ATG7 can still
form autophagosomes/ autolysosomes and perform autophagy-mediated protein
degradation when subjected to certain stressors. Moreover, they showed that
autophagosomes seemed to be generated in a Rab9-dependent manner by the fusion of
isolation membranes with vesicles derived from the trans-Golgi and late endosomes
[142].
Although at the genetic level cancer is caused by diverse mutations, epigenetic
modifications are characteristic of all cancers, from apparently normal precursor tissue
to advanced metastatic disease, and these epigenetic modifications drive tumor cell
heterogeneity. The recent discovery of several mutated epigenetic modifiers in human
cancer provides a potential mechanism by which DNA mutation might lead to
epigenetic alterations. Environmental factors, such as carcinogens, diet, ageing, injury
and inflammation, cause epigenetic reprogramming. The machinery for maintaining
epigenetic integrity can be stably disrupted in either of two ways: by mutation or by
epigenetic change itself with positive feedback [143].
Histone modification is important to show the status of chromatin structure.
Compared to methylation and phosphorylation, histone acetylation is probably the best
understood. Histone acetylation is usually associated with active transcription, which
is mediated by histone acetyltransferases (HATs) [144]. HATs can act as an oncogene;
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abnormal acetylation of histones at proto-oncogenes or acetylation of other
tumorigenic players can lead to hyperactivity of these genes or proteins and
consequently will enhance carcinogenesis. Abnormal recruitment to the wrong loci or
excess of the HATs due to pathological overexpression are typical mechanisms [145].
P300 is one of the well-known HATs and has been an area of study. Studies have
shown that P300 was targeted in prostate cancer treatment [146]. Additionally, another
study had shown that high expression of p300 in breast cancer may be important in the
acquisition of a recurrence phenotype and suggested that the high expression of p300
is an independent biomarker for poor prognosis of breast cancer patients [147]. Here,
we showed that both acetyl H3 and acetyl H4 were downregulated after cancer
treatment with RCE. Moreover, P300 expression level has declined as well, suggesting
that targeting acetylation in breast cancer might be of an importance in cancer
treatment. Histone modifications contribute to cancer metastasis by controlling
different metastatic phenotypes as those modifications were shown to have a role in
EMT and cancer metastasis [148]. This area needs further investigation to understand
the molecular mechanism by which histone modifications promotes cancer
progression and metastasis.
As described earlier, metastasis requires several crucial events such as cancer
cell adhesion, proteolytic degradation of ECM and angiogenesis. Current cancer
treatment drugs target cancer progression by blocking cell cycle, inducing cell death
and inhibiting tumor invasion and angiogenesis. Several natural therapeutic
compounds have been reported to target these events. Cancer’s ability to adhere to
components of the ECM is a required for cancer’s migration and thus represents one
of the central steps in metastasis.
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It has also been shown that the interaction of fibronectin which is a component
of the ECM with specific cell surface receptors such as integrins enhance the
metastatic potential of breast cancer cells and blocking this interaction through integrin
antibodies can inhibit the adhesion and migration of breast cancer cells [149]. In
agreement with our data, it was shown that at non-cytotoxic concentrations of RCE
adhesion of MDA-MB-231 to fibronectin as well as their migration were inhibited.
This inhibition may partly account for the anti-metastatic potential of RCE on breast
cancer cells.
Invasion involves the degradation of the ECM through many proteases, of
which MMP-9 appears to play a key role [150]. It has been shown that increased
expression of MMPs promote cell growth, aggressiveness and metastatic potential of
breast cancer cells [151]. Thus, inhibiting these proteases is an essential approach in
fighting breast cancer. Here, we demonstrate that RCE decreased MMP-9 levels and
consequently reducing ECM degradation.
Angiogenesis is a process by which new blood vessels are formed and it is
essential for tumor growth and metastasis. Prevention of this process would ultimately
inhibit both tumor growth and metastasis [152]. One way through which angiogenesis
can be blocked is by targeting pro-angiogenic factors secreted by tumor cells such as
VEGF. Actually, VEGF is considered to be a major pro-angiogenic factor expressed
in 60% of breast cancer patients [153]. Importantly, we found that RCE markedly
reduced VEGF production in MDA-MB-231 cells and therefore suggesting that one
possible mechanism through which RCE inhibits TNBC tumor growth is to block
angiogenesis process. Hypoxia-inducible factor-1 (HIF-1) has been known as an
important cancer drug target. Studies have shown a strong correlation between
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elevated levels of HIF-1 and tumor metastasis, angiogenesis and poor patient
prognosis. Moreover, HIF-1 has been taken as a key factor in regulation of VEGF and
VEGFR and other angiogenic factors. Recent advances in cancer biology highlighted
the HIF-1α pathway as an important survival pathway for which treatment strategies
to inhibit HIF-1α could be developed for cancer treatment [136, 154]. Interestingly,
we found that the expression of HIF-1α was also reduced after RCE treatment.
Suggesting that inhibition of VEGF and HIF-1 α could participate at least partly in the
inhibition of angiogenesis.
Accumulating evidences suggest a strong association between cancer
progression and inflammation [155]. Increased production of inflammatory cytokines,
such as IL-6 and TNF-α, are known to promote migration, invasion and metastasis of
different types of cancer including breast cancer [156]. Additionally, many studies
have identified IL-6 and TNF-α as key factors of poor prognosis in TNBC, given their
role in promoting invasion and metastasis [157-159]. Therefore, inhibition of these
signaling pathways offers a promising strategy for TNBC treatment. Additionally,
Hartman et al. reported that TNBC progression relies on coordinate autocrine
expression of IL-6 and inhibition of this cytokine lead to inhibition in colony formation
in vitro and tumor growth in vivo of TNBC cells [160]. Likewise, inhibition of breast
tumor growth by ulinastatin and docetaxel was associated with decrease in the
expression level of IL-6 and TNF- α [160]. Moreover, TNF- α induces the production
of IL-6 through ERK1 in breast cancer [161]. Interestingly, here we showed that RCE
inhibited both TNF-α and IL-6 production in MDA-MB-231 cells. Therefore, we
postulate that RCE inhibition of IL-6 occurs by its ability to suppress the TNF
signaling route. Altogether, our data suggests that a possible mechanism through
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which RCE inhibits invasion and tumor growth is by inhibiting IL-6 and TNF-α
pathways.
NFκB which is a transcription factor that play an important role transmitting
signals of inflammatory cytokines to the nucleus. NFκB signaling pathway can be
activated by TNF-α and is responsible for the activation of several genes involved in
metastasis and its inactivation have been associated with the suppression of metastasis
in breast cancer cells [162]. Additionally, the inactivation of NFκB in breast cancer
cells has been linked with the inhibition of the expression of many targeted genes
involved in metastasis and tumor growth such as MMP-9, VEGF and IL-6 [163]. In
this study, we showed that RCE inhibited the NFκ B signaling through downregulation
of phospho-p65 as well as MMP-9, VEGF and IL-6 which are the downstream targets
of NFκB. It is noteworthy to mention that RCE inhibited TNF-α in MDA-MB-231
cells as well. It seems that NFκB inhibition could account partly for the anti-metastatic
effects of RCE. We can hypothesize that one possible mechanism by which RCE exerts
its anti-metastatic and anti-tumor growth of TNBC involves the downregulation of
TNF-α.
Signal transducer and activator of transcription 3 (STAT3) is responsible for
mediating the transcription downstream of several cytokine, growth factor, and
oncogenic stimuli. Constitutive activation of STAT3 was described in different
cancers including breast cancer. The critical role of STAT3 in cancer cell survival,
proliferation, invasion, metastasis and angiogenesis is well-established. Due to this
central role, STAT3 is widely considered a good target for anti-cancer therapy [164].
Signaling through the IL-6/JAK/STAT3 pathway have been implicated in breast
cancer development and this pathway is thought to be activated by the binding of IL-
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6 to their receptors. Those receptors directly or indirectly induce STAT3 activation in
different breast cancers. Abnormal STAT3 signaling promotes breast cancer
progression through deregulation of downstream target genes which control
proliferation such as Survivin, Cyclin D1 and c-Myc, angiogenesis such as HIF-1α and
VEGF and EMT such as MMP-9 [165]. Interestingly, we found that RCE inhibited the
phosphorylation of STAT3 in MDA-MB-231 cells, thus suggesting that STAT3
inactivation might contribute to the anti-cancer effect of RCE. Most importantly, IL-6
production was also reduced in response to RCE. Thus, our data suggest that IL-6
production reduction might contribute partly to STAT3 inhibition in TNBC.
Flotillin-2, a major protein on lipid rafts, that have role in a number of cellular
mechanisms that are dysregulated in tumor cells, such as altered protein signaling and
trafficking. It is possible that abnormalities of Flotillin-2 protein contribute to the
formation of cancer-specific cellular characteristics [166]. Studies have shown that
Flotillin-2 may serve as a potential predictor of prognosis in early-stage breast cancer
[167]. Moreover, Wang et al. have shown that breast cancer cells show higher
expression of flotillin-2 compared to normal cells, and overexpression of flotillin-2
has been related to clinical stage, classification, tissue differentiation and the
expression of human EGFR [166]. As a regulator of lung metastasis, it was found that
the decrease in flotillin-2 protein expression reduces the metastatic ability of breast
cancer in vivo [168]. It was also reported that depletion of flotillin-2 lead to an impaired
cell migration of breast cancer [169]. Taken the previous studies together, Flotillin-2
appears to be a hot target in cancer treatment. In this study, RCE led to a decrease in
the expression level of Flotillin-2 in MDA-MB-231 cells, suggesting that Flotillin-2
might participate at least partly to the inhibition of metastatic potential of MDA-MB231 cells.
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5.2 Colon cancer
In the present study, we examined the potential anti-cancer activity of RCE on
colon cancer. Our findings demonstrated that RCE inhibited the viability and colony
growth of colon cancer cells through inactivation of proteasome-dependent
degradation of mTOR. Actually, we found that RCE treatment, stimulated protein
ubiquitination and proteasome degradation of proteins including caspase-3, AKT and
p53 at the beginning. We suggest that this early event serves as a trigger for promoting
non-canonical Beclin-1-independent autophagy and subsequent autophagy-dependent
caspase-7-dependent apoptosis which ultimately leads to cell death in colon cancer
cells.
Herbal extracts and their compounds are well known for their efficiency in
inhibiting cell growth and promoting cancer cell death through different mechanisms
including autophagy and apoptosis. In this study, RCE was tested against breast cancer
and colon cancer cells. It is worth to mention that Rhus coriaria was shown to be safe
to consume by both humans and animals. In fact, rats fed with doses up to 1 g/kg of
lyophilized extract showed no signs of toxicity or mortality [170].
One crucial factor in the coordination of overall protein turnover is Ser/Thr
protein kinase mammalian target of rapamycin (mTOR), which promotes growth and
regulates amino acid, glucose, nucleotide, fatty acid and lipid metabolism [171]. In
order to be activated, mTORC1 translocate from the cytoplasm to the lysosomal
surface, where it is activated by growth factors via PI3K– AKT signaling [172, 173].
Activated mTOR coordinates the overall protein turnover and thus promoting cell
growth and proliferation [171]. On the other hand, inhibition of mTOR can induce
autophagy in eukaryotic [174]. The PI3K/AKT/mTOR pathway is hyperactivated in
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many cancers, including colorectal cancer, and is crucial for cancer progression and
cancer cell survival [174]. Therefore, mTOR has emerged as a potential target for drug
development. Several mTOR inhibitors have already gone through clinical trials for
treating various cancers including colorectal cancer [175]. Temsirolimus and
Everolimus, are two commercially available mTOR inhibitors approved by the
European Medicines Agency in the European Union, and Food and Drug
Administration in the United States [176]. Rapamycin, the first discovered natural
inhibitor of mTOR, was shown to suppress advanced stage colorectal cancer
[177]. Other mTOR inhibitors have been used in colorectal cancer treatment and the
role of mTOR inhibitors continues to evolve, as new compounds are synthetized. In
this study we found that AKT and mTOR were targeted to proteasome-dependent
degradation, along with other proteins upon RCE treatment. Interestingly, our data
reveled that mTOR degradation occurred as early as 3 h after-treatment alongside an
increase in the level of protein ubiquitination. AKT depletion occurred only 12 h after
treatment with RCE, a time at which autophagy was already induced. This might
suggest that mTOR suppression occurs through an AKT-independent mechanism.
Which suggest that the effect of RCE in colon cancer may be initiated, at least partly,
through the degradation and consequent inactivation of mTOR. Our data are in
agreement with this claim, since proteasomal inhibition by MG-132 restored total
mTOR level, restored the phosphorylated mTORC1, blocked autophagy and reduced
cell death in HT-29 cells induced by RCE.
Increasing number of anticancer therapies has been shown to stimulate
autophagy pathways that mediate autophagic cell death [178]. In this study we showed
that RCE induced autophagy in colon cancer cells. Based on the findings that include
intracellular cytoplasmic vacuolation, modulation of autophagy-specific markers such
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as conversion of LC3-I to LC3-II and induction of p62 (SQSTM1) accumulation. This
agrees with the finding on breast cancer cells in which RCE also induced autophagy.
In contrast to breast cancer in which RCE induced beclin-1 dependent autophagy
[179], here we show that RCE induced beclin-1 independent autophagy in colon cancer
cells. Indeed, we found that RCE promoted beclin-1 degradation by the proteasome
and inhibition of the proteasome using MG-132 restored beclin-1 to a level comparable
to non-treated control cells. Similar findings were found by other studies on
resveratrol, a natural compound, which was shown to induce canonical autophagy in
human colorectal cancer cells [180] and non-canonical beclin-1 independent
autophagy in breast cancer cells [181]. It appears that the type of autophagy induced
in response to anti-cancer drugs depends mainly on the cell type.
Increasing number of studies showed that autophagosome induction can still
occur in the absence of key autophagy actors such as beclin-1 [182]. Non-canonical
beclin-1-independent autophagy has also been reported in cell treated with compounds
that possess anti-cancer activities such as carnosol [182] and cobalt chloride [183]. It
is worthy to mention that non-canonical beclin-1-independent autophagy was induced
in beclin-1-depleted HeLa cells in response to cobalt chloride [184]. In agreement with
the previous mentioned studies, we found that RCE targeted beclin-1 to degradation
by the proteasome and also induced beclin-1 independent autophagy in colon cancer
cells. Based on these results, we can suggest that non-canonical autophagy can be
induced when the function of canonical autophagy proteins is compromised.
Apoptosis and autophagy are two different mechanisms with different key
players and cross-talk between them exists, however, the interplay between these two
mechanisms remains a big challenge for cancer therapy. Autophagy has a dual role in
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the cancer cell, it either contributes to cytoprotective events that promote cancer cell
survival and avoiding apoptosis or it can stimulate a pro-death signal pathway in
cancer cells which ultimately lead to cell death. Additionally, under some
circumstances, autophagy and apoptosis can exert synergetic effects, while in other
cases autophagy can be triggered only when apoptosis is suppressed [185, 186].
Therefore, the relation between autophagy and apoptosis may depend upon the cell
type, nature and duration of stimulus [187]. In this study we found apoptosis is induced
upon RCE treatment, however it is not the main mechanism of cell death. As we found
that the main mechanism of cell death might occur as a result of excessive autophagy.
This claim is based on several results. First, we illustrated that autophagy occur before
apoptosis. Time course experiments provided the evidence that autophagy activation
occurred after 12 h of RCE treatment and the inhibition of cell viability was observed
already after 24 h after RCE treatment. On the other hand, apoptosis was detected after
48 h, shown by the activation of apoptotic markers such as caspase-7 activation and
PARP cleavage. In addition to that, autophagy inhibition by CQ rescued cancer cell
death induced by RCE while pre-treating cells with pan-caspase inhibitor had almost
no effect on cell death. Our results also showed that even though caspase-3 is depleted
due to its proteasome-dependent degradation in HT-29 cells treated with RCE, the
mechanism for apoptosis is still functional. Here we showed that HT-29 cells were
able to induce apoptosis through caspase-7 dependent pathway. In agreement with our
result, a study showed that induction of caspase-7-dependent apoptosis was observed
in caspase-3 deficient breast cancer cells when treated with Styrylpyrone Derivative
(SPD), a plant-derived active compound [188]. These results suggest that apoptotic
cell death comes as secondary response to the increased intracellular stresses and
therefore accumulation of cellular damage due to longer exposure of the cells to RCE.
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The balance between the regulation of protein turnover and nutrient availability
determines the overall status of cell growth. When nutrients are abundant, protein
synthesis rates elevate, while protein degradation are kept to minimal. Whereas in
energy-stressed cells, synthesis drops with rise in overall degradation [189]. One
crucial factor in the coordination of overall protein turnover is Ser/Thr protein kinase
mammalian target of rapamycin (mTOR), which promotes growth and suppresses
autophagy [171].
mTOR inhibition, due to cell starvation or direct experimental inhibition, is
known to induce autophagy and stimulates protein breakdown [190]. Recent studies
have established that proteolysis through the UPS is also regulated by mTORC1.
Conversely, it is yet to be concluded whether it stimulates or suppresses the UPS
activities, due to the contradictory nature of these studies, where the first study
reported that inhibition of mTORC1 reduced proteolysis through suppressing the
expression of proteasome [53], whilst the second reported the opposite, sighting that
the inhibition of mTOR stimulates and enhances both autophagy and proteolysis by
UPS [138]. Our results are in agree with the second study. We found that the earliest
effect that was observed at 3 h after RCE treatment was an increase in the overall level
of protein ubiquitination and the degradation of total mTOR protein. The mechanism
by which inhibition of mTOR stimulates proteasome degradation deserves more
investigations.
Until recently, autophagy and UPS degradation pathways were referd to as
independent events. Conversely, recent studies showed that ubiquitination can target
several proteins for degradation through both mechanisms [191]. In our case, we
speculate that autophagy may be induced as secondary event that serves as back-up
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mechanism to help removing aggregated or misfolded proteins when the function of
the proteasome system is overwhelmed due to excessive accumulation of damages.
Indeed, we showed that autophagy was blocked when proteasomal function was
inhibited by MG-132.
The tumor suppressor protein p53 which is mutated in about 50% of human
cancers [192] had been found to be chemo-resistant to many used anti-cancer drugs
and was known to enhance cell division and invasion [193]. Depletion of mutant p53
was shown to reduce cell proliferation, inhibit tumorigenicity and increase the
susceptibility of colon cancer cells to anticancer drugs [194]. Therefore, mutant p53 is
considered to be a potential target for cancer treatment [195]. Studies have shown that
mutant p53 evade proteasomal-dependent degradation, which allow it to accumulate
in response to stresses and this accumulation seems to have a role in cancer
development and progression [196]. Moreover, studies showed that oxidative stress
and DNA damage promote stabilization of mutant p53 that is required for its oncogenic
function [197]. A current therapeutic strategy to inhibit mutant p53 function is to target
it to degradation through autophagy and proteasomal processes [139]. In this study we
showed that RCE promoted proteasomal degradation of mutant p53 in HT-29 cells,
since inhibition of the proteasomal activity rescued p53 from degradation and reduced
cell death in RCE treated cells. However, inhibition of autophagy had no effect on p53
protein level. The molecular mechanism through which RCE targets mutant p53 to
proteasomal degradation is still not know and deserves further exploration.
Cyclin D1 is often deregulated in cancer and considered to be a biomarker of
cancer progression. The capacity of cyclins to activate the cyclin-dependent kinases
(CDKs) is a well-documented mechanism for their oncogenic activities and provides
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an attractive therapeutic target. It has been illustrated that some genes such as
thrombospondin and the Rho effector ROCK2 respond to cyclin D1 promote migration
and invasion [139]. It was also shown that migration of epithelial cells and
macrophages was reduced in the absence of cyclin D1 [198]. Interestingly, cyclin D1
was not able to promote migration after p27 knockdown [199] suggesting that cyclin
D1 and p27 are related and both might be required for migration process. p27 which
is a cyclin-dependent kinase (Cdk) inhibitor have been shown to regulate cell
proliferation, cell motility and apoptosis [200]. In this study, we found that both cyclin
D1 and p27 were downregulated in HT-29 cells upon RCE treatment; which suggest
that the inhibition of migration might occur partly by inhibiting those proteins.
However, the mechanism of action and how they are involved needs further
investigation.
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Chapter 6: Conclusion
Chemoprevention by edible phytochemicals is now believed to be an
accessible approach for cancer control. Various phytochemicals derived from edible
plants have been shown to interfere with different stages of tumorigenesis. Many
cellular processes and mechanisms have been shown to account for the anticarcinogenic actions of dietary components, but attention has recently been focused
on intracellular signaling cascades as common molecular targets for various chemopreventive phytochemicals.
Here, we demonstrate that RCE exerts a potent anti-angiogenic, anti-metastatic
and anti-tumor growth effects on TNBC by targeting multiple key pathways employed
by TNBC to acquire a rather aggressive phenotype. Moreover, our data also shows the
effect of RCE on mutant p53 colon cancer cells. RCE, stimulates overall intracellular
protein ubiquitination associated with proteasome degradation of component of
negative regulator of autophagy pathway.
Our findings provide the first instance of a potential role for Rhus coriaria as
an anti-cancer agent against breast and colon cancer and certainly deserves more
attention for further explorations to identify novel effective therapeutic compound(s)
against TNBC and colon cancer.
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